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ABSTRACT
The pathogenic bacterium Staphylococcus aureus encounters a variety of immune
cells that restrict bacterial growth and dissemination during infection. However, S. aureus
counters these immune cell functions by producing myriad virulence factors that facilitate
evasion of host defense strategies. Therefore, it is important to understand S. aureusimmune cell interactions and the virulence factors that perturb normal immune function
to promote pathogenesis. In a genetic screen designed to identify S. aureus secreted
factors that positively or negatively modulate macrophage activity our lab identified a
transposon insertion mutant in the gene SAUSA300_1984, encoding a putative membrane
spanning peptidase. To investigate the role of 1984 in pathogenesis, I generated a Δ1984
mutant and found it behaves like a quorum sensing system mutant, Δagr, with defects in
protein secretion and macrophage activation. The Agr system requires proper processing
of a signaling peptide, AgrD, via cleavage of its C-terminus by AgrB and cleavage of its
N-terminus by an unknown peptidase. Given this information, I hypothesized that 1984 is
a peptidase is involved in processing AgrD.
If 1984 is involved in AgrD processing, then loss of its activity will perturb
virulence factor production, enhance immune cell activity, and attenuate virulence. Thus,
this study aimed to determine how this membrane-spanning putative peptidase elicits
global changes in virulence factor gene expression, via the Agr system, with subsequent
influences on macrophage activation and pathogenesis.
x

CHAPTER ONE
LITERATURE REVIEW
Staphylococcus aureus can lead to severe infections.
Staphylococcus aureus is a major cause of infectious conditions such as sepsis,
endocarditis, toxic shock syndrome, and bacteremia. Both hospital-acquired and
community-acquired S. aureus infections have increased in recent decades leading to a
62% increase in hospitalizations from 1999 to 2005 (1) and thousands of deaths per year
(2, 3). Part of this increase is attributed to the increased incidence of antibiotic resistance
among infectious isolates as evidenced by a doubling in the number of methicillinresistant S. aureus (MRSA)-related hospitalizations over a six-year period (1). Despite
being a major cause of these serious illnesses, S. aureus is also a common transient
commensal and colonizes up to 50 percent of healthy adults (4). Typically, infections
occur when S. aureus breaches the skin or mucosal barriers. Upon entry into a sterile site,
S. aureus encounters a rapid pro-inflammatory innate immune response that poses a
significant obstacle to bacterial dissemination. The interactions between S. aureus and
some of these immune cells, such as neutrophils, are very well studied (5) while other
interactions, such as between S. aureus and macrophages, are less well understood. It is
known that S.aureus uses complex and redundant virulence gene regulatory systems to
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produce an array of cytotoxins and immunomodulatory proteins that promote evasion of
immune surveillance mechanisms and promote bacterial survival during infection.
S. aureus virulence factor gene expression is controlled by complex
regulatory systems. The ability of S. aureus to colonize a wide range of tissues and
cause acute and chronic disease is partially due to its use of complex regulatory systems
that control the expression of a myriad virulence factors. Of these virulence factors, S.
aureus secretes toxic proteins that can cause tissue damage and facilitate the spread of
infection, as well as surface proteins that promote resistance to phagocytosis or
antimicrobial peptides (6). These virulence factors are often regulated at multiple levels
including translation, transcription, and degradation (7). S. aureus employs 16 twocomponent systems as a part of its regulatory network (7). Furthermore, many of these
two-component regulatory systems not only directly control gene expression, but also
control expression of regulatory RNAs (7). One example of a major two-component
regulatory system in S. aureus that regulates virulence factor production as well as a
regulatory RNA is the Accessory Gene Regulatory system, or Agr system.
A peptide-based quorum sensing system regulates virulence factor gene
expression in S. aureus. The Agr system is a well-documented peptide-based quorum
sensing system involved in promoting secretion of major S aureus virulence factors
(Figure 1). All of the known components of the Agr system are transcribed from the P2
promoter as a polycistronic mRNA with 4 open reading frames (8). Agr is comprised of
AgrA, a response regulator (9), AgrB, a metalloprotease that modifies AgrD and aids in
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transport of processed peptide (10-13), AgrC, a histidine kinase (14), and AgrD, the
precursor of the auto-inducing peptide, AIP. Clinical isolates of S. aureus contain one of
four distinct Agr groups, each with a sequence specific AgrD (Groups I, II, III, and IV)
(15, 16). AgrD recognition is group specific and each of the four AgrD variants inhibits
the activity of their respective non-cognate Agr groups (16). AgrD is a peptide composed
of 46 amino acids that is post-translationally modified and processed in order to generate
a functional AIP (Figure 1B). The N-terminal 18 residues form an α-helix that anchors
the peptide to the cell membrane by lateral association (17). This anchoring seems to be
required for processing of AgrD. Previously, it was shown that AgrB is involved in AgrD
post-translational processing. AgrB is a multipass membrane protein with a catalytic dyad
required for cleavage of the C-terminal end of the peptide between the methionine of the
AIP and an aspartic acid (11, 12)(Figure 1B). This processing event is Agr group specific
(10, 11). In addition, AgrB catalyzes the efficient and reversible cyclization of AgrD
(18). This cyclization reaction leads to the formation of a thiolactone linkage between the
C-terminal carbonyl and the sulfur atom present in a cysteine side chain of AIP (19). The
thiolactone is required for recognition by the Histidine kinase, AgrC (20). The
degradation of the C-terminal cleavage product from AgrD is a key component of AIP
synthesis, as its degradation is predicted to provide the energy required for the thiolactone
formation (18). Additionally, AgrB is hypothesized to have a direct role in secretion of
the processed AIP (13).
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Figure 1. The accessory gene regulatory system in S. aureus. (A)The Agr quorum sensing system in S.
aureus is comprised of: the autoinducing peptide precursor, AgrD; a protease involved in cleaving the Cterminal end of AgrD, AgrB; a histidine kinase, AgrC, and the transcription factor, AgrA. Modified from a
figure made by Dr. Alonzo. (B) Depiction of posttranslational modifications of AgrD.

While much of the AIP biosynthesis pathway has been elucidated, the processing
of the N-terminal end of AgrD remains unclear. A number of studies have concluded that
AgrB does not perform N-terminal cleavage of AgrD (12, 18) and that peptide
translocation occurs prior to the N-terminal cleavage event (21). Peptide translocation
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prior to cleavage is supported by recent work that found the N-terminal end of AgrD is
present in cell free supernatant and that these fragments have both cytotoxic and
proinflammatory activities (22). In 2007, Kavanaugh et al (23) put forward the hypothesis
that the Type I Signal Peptidase, SpsB, is the peptidase required for processing the Nterminus of AgrD. However, there are some caveats to their study that warrant further
investigation of other possible peptidases as mediators of AgrD cleavage. First, the fixed
concentration of AgrD peptide used to detect cleavage events was below the binding
affinity for most peptidases. Second, the authors suggested SpsB is responsible for
peptide cleavage based upon protease inhibitor studies that were not fully validated for
blockade of protease activity. Due to these complications associated with specificity of
protease inhibition, the authors were unable to eliminate the possibility that other
peptidases might also be involved in cleaving AgrD; thus, they were unable to
definitively ascribe a role for SpsB as the only peptidase involved in cleavage.
Furthermore, when the authors generated a mutation in the AgrD peptide that would be
predicted to inhibit SpsB activity, they were unable to prevent cleavage. In addition, a
review by Wang et al (21) notes that currently only indirect evidence for a role of SpsB in
peptide cleavage is indicated. Based on the methods used for this study and the evidence
presented, we suggest that SpsB is not the only N-terminal modifier of AgrD. In this
thesis, we hypothesize that another peptidase is responsible for processing the N-terminus
of AgrD to generate AIP.
Once AgrD is processed and exported, the processed AIP accumulates in the
extracellular space (Figure 1). As the concentration of AIP increases, the histidine kinase
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AgrC recognizes the AIP, leading to AgrC activation. AgrC then phosphorylates and
activates the response regulator, AgrA (14). AgrA is comprised of two domains, an Nterminal receiver domain that dimerizes and a C-terminal DNA binding domain with
consensus DNA elements (24). Active AgrA then binds to the P2 promoter to upregulate
the remainder of the system. AgrA also binds to a promoter known as P3, which directly
regulates virulence factor expression including genes encoding major toxins and
hemolysins (9).
The Agr pathway affects expression of a wide range of virulence factors that
facilitate pathogenesis. AgrA upregulates the transcription of a regulatory RNA known
as RNAIII, which interacts with target mRNAs and either facilitates their degradation or
increases their stability and translation efficiency (25, 26). One degradation target of
RNAIII is the mRNA that encodes the transcription factor repressor of toxins, Rot (26).
The down regulation of Rot translation by RNAIII leads to reduced production of surface
proteins such as Protein A, the antibody binding protein used by S. aureus to resist
phagocytosis as well as prevent B-cell receptor cross-linking (27). Protein A binds the
Fcγ domain of IgG positioning the antibody in the incorrect orientation on the surface of
S. aureus leading to decreased opsonization and phagocytosis efficiency (28, 29).
Additionally, Protein A can bind to immunoglobulin on the surface of B cell receptors
leading to clonal expansion resulting in apoptosis, thereby decreasing the amount of
antibody produced (30). Furthermore, it has been shown that mice infected with a Protein
A mutant have less kidney abscesses than mice infected with wild type S. aureus (28).
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The down regulation of Rot by RNAIII also leads to increased expression of the
toxins Rot normally represses which includes a diverse array of virulence factors. For
example, the β-barrel pore–forming toxin, alpha toxin, is regulated by RNAIII and is used
by S. aureus to lyse red blood cells and epithelial cells as well as modulate neutrophil
functions (31). The alpha toxin binds to a host cell receptor, ADAM10, and forms a
heptameric pore in host cell membranes leading to cell death (32). This toxin is crucial
for the pathologic outcomes associated with skin and soft tissue infection and bacteremia,
but is not required for early establishment of abscess lesions (31, 33, 34). Other
examples of Agr regulated virulence factors are the leukotoxins AB and ED, which are
involved in targeted destruction of leukocytes (35, 36), as well as the Phenol-soluble
modulins (PSMs), a group of peptide toxins that are involved in red and white blood cell
lysis (37), biofilm formation (38), and receptor-mediated inflammatory responses(39,
40). Recent research has shown that PSMs are vital for phagosomal escape, while LukAB
is a major factor involved in inducing cell death and bacterial escape from macrophages,
all functions that are required for bacterial survival and dissemination (41, 42).
The above examples only touch the surface of the considerable number and types
of virulence factors, regulated by Agr, and contributing to S. aureus pathogenesis.
Because of its broad capacity to alter the expression of such a wide range of virulence
mediators, the Agr locus is one of the most extensively regulated loci in S. aureus. It
receives additional regulatory inputs from many secondary regulators, including those
with repressive functions to dampen imappropriate gene expression (7). These gene
expression complexities are illustrated by the varied secondary inputs that alter RNAIII
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expression in clinical isolates. For example, the primary infectious isolate in the United
States, USA300, has higher levels of RNAIII compared to other lineages (7). It is
suggested that the increased toxin production associated with increased steady-state
RNAIII levels may provide an explanation for the enhanced virulence of this communityacquired MRSA strain (7). Thus, it is clear that the stringent regulation and interactions
of protein products of the Agr system have the potential to dramatically influence clinical
infection outcomes. Elucidating the precise mechanisms of Agr function is necessary for
improving our understanding of S. aureus pathogenesis as well as allowing us to examine
the Agr system as a possible drug target.
Abortive infectivity proteins and CAAX proteases in peptide processing.
Many bacterial species contain genes that encode a family of proteins known as
abortive infectivity (Abi) proteins. Abi proteins are widely understood to facilitate selfimmunity against phage infections through an array of mechanisms including delay of
DNA replication or inhibition of phage protein synthesis (43). To prevent bacteriophage
from spreading, some Abi proteins promote bacterial self-sacrifice to block propagation
of an infection (43-45). Other Abi proteins contribute to surface protein display and cell
division in S. aureus (45). In addition, some Abi proteins have been shown to function as
metalloproteases involved in bacteriocin maturation, as is seen in Lactobacillus
plantarum and Streptococcus pneumonia (46), while others function in toxin anti-toxin
systems as well as bacteriocin self-immunity (46, 47). Clearly, there is a wide range of
functions associated with Abi proteins despite their highly conserved motifs (48): two
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glutamates, three additional residues, and an arginine (EEXXXR) as well as a second
motif containing phenylalanine, three residues, and a histidine (FXXXH).
Abi protein domains are related to the CAAX protease family (48). The CAAX
family is made up of metalloproteases that promote protein localization at the membrane
by recognizing and prenylating a CAAX motif on the C-terminal end of their target
protein (49). Prenylation is the process that covalently attaches lipid molecules to
proteins to facilitate membrane localization. Similar to Abi proteins, other CAAX
proteases have also been found to be involved in bacteriocin maturation and modification
of small peptides (48). Because these proteins have such a wide range of functions, it is
difficult to assign specific activities to an Abi or CAAX protein based on its conserved
domains alone.
Preliminary studies conducted by Dr. Alonzo used a transposon mutant library to
screen for secreted factors that elicited altered macrophage activation. One mutant that
was identified had a diminished exoprotein profile compared to wild type S. aureus as
well as elicited a heightened IL-1β response when supernatants from the mutant were
applied to murine bone marrow derived macrophages. The SAUSA300_1984 gene
encodes a putative membrane spanning peptidase that is 247 amino acids in length and
contains conserved Abi protein family motifs (Figure 2). Additionally, the protein
encoded by the 1984 gene has ten predicted membrane-spanning domains with both its
N-terminal end and its C-terminal end inside of the cell. When the function of 1984 was
investigated alongside other proteins from S. aureus with conserved Abi domains, 1984
had no apparent role in surface protein display and cell division (45). However this study
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only examined the surface display of Protein A in depth. 1984 also contains a predicted
CAAX prenyl protease domain. It is currently unclear how these domains may play a role
in the function of 1984. However, based on the homology to Abi proteins and CAAX
proteases, I hypothesized 1984 may function as a peptidase and chose to investigate the
role of 1984 in S. aureus peptide processing. Furthermore, based on the data provided
from the transposon mutant library screen, 1984 might be involved in altering optimal
macrophage responses and facilitating pathogenesis. The goal of the study described in
this thesis was to define the role of 1984 in S. aureus quorum sensing and virulence
during infection.
M T R L W A S L L T V I I Y I L S Q F L P L L I V K
K L P F V Q Y S G I E L T K A V I Y I Q L V L F L I
A A T T I I L I N L K I K N P T K L E L E V K E P K
K Y I I P W A L L G F A L V M I Y Q M V V S I V L T
Q I Y G G Q Q V S P N T E K L I I I A R K I P I F I
F F V S I I G P L L E E Y V F R K V I F G E L F N A
I K G N R I V A F I I A T T V S S L I F A L A H N D
F K F I P V Y F G M G V I F S L A Y V W T K R L A V
P I I I H M L Q N G F V V I F Q L L N P E A L K K A
Q contains
A N F aIconserved
Y H I CAAX
F I Pdomain. The amino acid sequence of 1984 is shown. In red
FigureT2.E1984
are conserved Abi motifs, while the CAAX domain hit is highlighted in yellow.

Conclusions.
S. aureus produces a wide range of virulence factors that promote evasion of
immune surveillance mechanisms and promote survival during infection. The rise in S.
aureus infection incidence is thought to be partially due to alterations in virulence factor
gene expression allowing more efficient immune evasion. Furthermore, S. aureus uses
complex regulatory systems, including the Agr quorum sensing system, during the course
of infection to promote survival. Given my identification of 1984, a novel Abi-like
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protein that modulates macrophage activation and has defects in protein secretion, I
sought to define its role in facilitating pathogenesis in S. aureus.

CHAPTER TWO
MATERIALS AND METHODS
Bacterial strains and culture conditions.
For the purposes of this study, all recombinant plasmids were passaged through E.
coli before propagation in S. aureus. E. coli DH5α was used for most plasmid
propagation. When constructing a 1984 complementation vector, I found that 1984 was
toxic in E. coli, therefore E. coli BH10C was used as a host strain; BH10C reduces copy
number of plasmids to near single-copy levels to limit expression of the toxic gene in E.
coli (50). Once passaged through E. coli, S. aureus RN4220 or RN9011
(RN4220+pRN7023) were used as intermediate strains that are amenable to DNA uptake.
Following propagation in one of these strains plasmids could then be introduced into
clinical isolates. S. aureus LAC (AH-1263) was used as the wild type strain for this
study. LAC (AH-1263) is a S. aureus USA300 isolate cured of its plasmids (51). All
strains used and constructed in this work are described in Table 1. All E. coli strains were
grown in Lysogeny Broth (LB) (Amresco), while S. aureus strains were grown in either a
rich medium, Tryptic Soy Broth (TSB) (Criterion), or defined medium, Roswell Park
Memorial Institute medium (RPMI) (corning) supplemented with 1% casamino acids
(Amresco) and 2.4 mM Sodium bicarbonate (Amresco). These two different media were
used because S. aureus can differentially regulate gene expression upon culture in either
medium. Additionally, antibiotics were used when necessary for
12
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plasmid selection as well as mutagenesis protocols. Media were supplemented with
antibiotics at the following concentrations: ampicillin (Amp) at 100μg/mL, erythromycin
(Erm) at 10 μg/mL, chloramphenicol (Cm) at 10 μg/mL, anhydrous tetracycline (AnTet)
(Acròs Organics) at 1 μg/mL, and tetracycline (Tet) at 10 μg/mL (Amresco and Acròs
Organics). In order to monitor bacterial growth, optical density at 600 nm (OD600) was
measured using a Genesys 10S UV-Vis spectrophotometer (Thermo).
Strain

Description

Designation

Source/
Reference

AH-1263

S. aureus USA300 Strain LAC. Plasmid cured.

LAC (WT)

(51)

DH5α
BH10C

E. coli strain for recombinant plasmids
E. coli strain that restricts plasmid copy number for
complementation of 1984

DH5α
BH10C

(50)

RN4220

Restriction deficient S. aureus

RN4220

(52)

RN9011

RN4220+ pRN7023 exressing SaPI1 Integrase

RN9011

(53)

FA-S922

LAC (AH-1263 – plasmid cured) with an in-frame
deletion of 1984
FA-S922 complemented with pJC1112-1984

Δ1984

This work

Δ1984+1984

This work

LAC gene replacement mutant of agrBDCA with
tetracylcine resistance cassette

Δagr::tet

LAC (AH-1263) gene replacement mutant of
agrBDCA with tetracylcine resistance cassette
FA-S922 transduced with Δagr::tet mutation

Δagr::tet

This work

Δ1984 Δagr::tet

This work

FA-S982

FA-S1008
FA-S995
AH-E462
FA-S945
FA-S949
FA-S984
FA-S1009
FA-S1011
FA-S1013
FA-S1014
FA-S1027

E. coli containing reporter plasmid pDB59 with gfp
expression driven by the P3 promoter
FA-S922 with GFP reporter plasmid pDB59

(54)
Δ1984+pDB59

This work

LAC (AH-1263) with GFP reporter plasmid
pDB59
LAC Δagr with GFP reporter plasmid pDB59

WT+pDB59

This work

Δagr+pDB59

This work

LAC (AH-1263) with pJC1112-agrBD w/ N
terminal 6x-His
FA-S995 with pJC1112-agrBD w/ N terminal 6xHis
FA-S1008 with pJC1112-agrBD w/ N terminal 6xHis
FA-S922 with pJC1112-agrBD w/ N terminal 6xHis
LAC (AH-1263) with pJC1112-agrBD w/ C
terminal 6x-His

WT+6xHis-agrBD

This work

Δ1984 Δagr+6xHisagrBD
Δagr+6xHis-agrBD

This work

Δ1984+6xHis-agrBD

This work

WT+agrBD-6xHis

This work

This work

14
FA-S922 with pJC1112-agrBD w/ C terminal 6xHis
FA-S995 containing pOS1-Phrt-agrD with a 6xHis-tag on the C-terminal end. This is a hemin
inducible promoter.
FA-S1008 containing pOS1-Phrt-agrD with a 6xHis-tag on the C-terminal end
FA-S995 containing pOS1-Phrt-agrD with a 6xHis-tag on the N-terminal end.
FA-S1008 containing pOS1-Phrt-agrD with a 6xHis-tag on the N-terminal end

Δ1984+ agrBD-6xHis

This work

Δ1984 Δagr+ pOS1Phrt-agrD+6xHis

This work

Δagr +pOS1-PhrtagrD-6xHis
Δ1984 Δagr +pOS1Phrt-6xHis-agrD
Δagr+pOS1-Phrt6xHis-agrD

This work

LAC (AH-1263) containing pOS1-Phrt-agrD with a
6x-His-tag on the C-terminal end
FA-S922 containing pOS1-Phrt-agrD with a 6xHis-tag on the C-terminal end
LAC (AH-1263) containing pOS1-Phrt-agrD with a
6x-His-tag on the N-terminal end
FA-S922 containing pOS1-Phrt-agrD with a 6xHis-tag on the N-terminal end
LAC (AH-1263) containing pOS1-Plgt-agrD with
6x-His-tag on the N-terminal end

WT+pOS1-PhrtagrD-6xHis
Δ1984+pOS1-PhrtagrD-6xHis
WT+pOS1-Phrt6xHis-agrD
Δ1984+pOS1-Phrt6xHis-agrD
WT+pOS1-Plgt6xHis-agrD

This work

FA-S922 containing pOS1-Plgt-agrD with 6x-Histag on the N-terminal end
FA-S1008 containing pOS1-Plgt-agrD with 6x-Histag on the N-terminal end

Δ1984+pOS1-Plgt6xHis-agrD
Δagr+pOS1-Plgt6xHis-agrD

This work

FA-S995 containing pOS1-Plgt-agrD with 6x-Histag on the N-terminal end
LAC (AH-1263) containing pOS1-Plgt-agrD with
6x-His-tag on the C-terminal end

Δ1984 Δagr+pOS1Plgt-6xHis-agrD
WT+pOS1-Plgt-agrD6xHis

This work

FA-S1097

FA-S922 containing pOS1-Plgt-agrD with 6x-Histag on the C-terminal end

Δ1984+pOS1-PlgtagrD-6xHis

This work

FA-S1098

FA-S1008 containing pOS1-Plgt-agrD with 6x-Histag on the C-terminal end
FA-S995 containing pOS1-Plgt-agrD with 6x-Histag on the C-terminal end

Δagr+pOS1-PlgtagrD-6xHis
Δ1984 Δagr+pOS1Plgt-agrD-6xHis

This work

LAC (Ah-1263) containing pOS1-PHELP-agrD with
6x-His-tag on the N-terminal end
FA-S922 containing pOS1-PHELP -agrD with 6xHis-tag on the N-terminal end

WT+pOS1-PHELP6xHis-agrD
Δ1984+pOS1-PHELP6xHis-agrD

This work

FA-S1008 containing pOS1- PHELP -agrD with 6xHis-tag on the N-terminal end
FA-S995 containing pOS1- PHELP -agrD with 6xHis-tag on the N-terminal end
LAC (Ah-1263) containing pOS1-PHELP -agrD with
6x-His-tag on the C-terminal end
FA-S922 containing pOS1-PHELP -agrD with 6xHis-tag on the C-terminal end
FA-S1008 containing pOS1-PHELP -agrD with 6xHis-tag on the C-terminal end
FA-S995 containing pOS1-PHELP -agrD with 6xHis-tag on the C-terminal end

Δagr+pOS1-PHELP6xHis-agrD
Δ1984 Δagr+pOS1PHELP-6xHis-agrD
WT+pOS1-PHELPagrD-6xHis
Δ1984+pOS1-PHELPagrD-6xHis
Δagr+pOS1-PHELPagrD-6xHis
Δ1984 Δagr+pOS1PHELP-agrD-6xHis

This work

FA-S1029
FA-S1082
FA-S1083
FA-S1084
FA-S1085
FA-S1086
FA-S1087
FA-S1088
FA-S1089
FA-S1092
FA-S1093
FA-S1094
FA-S1095
FA-S1096

FA-S1099
FA-S1133
FA-S1134
FA-S1135
FA-S1136
FA-S1137
FA-S1138
FA-S1139
FA-S1140

This work
This work

This work
This work
This work
This work

This work

This work

This work

This work

This work
This work
This work
This work
This work
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LAC (AH-1263) containing pOS1-PsarA- sodRBS agrD with 6x-His-tag on the N-terminal end
FA-S922 containing pOS1-PsarA- sodRBS -agrD
with 6x-His-tag on the N-terminal end
FA-S1008 containing pOS1-PsarA- sodRBS -agrD
with 6x-His-tag on the N-terminal end

WT+ pOS1-PsarAsodRBS -6xHis-agrD
Δ1984+ pOS1-PsarAsodRBS -6xHis-agrD
Δagr+ pOS1-PsarAsodRBS -6xHis-agrD

This work

FA-S1144

FA-S995 containing pOS1-PsarA- sodRBS -agrD
with 6x-His-tag on the N-terminal end

This work

FA-S1145

LAC (AH-1263) containing pOS1-PsarA- sodRBS agrD with 6x-His-tag on the C-terminal end

Δ1984 Δagr+ pOS1PsarA- sodRBS -6xHisagrD
WT+ pOS1-PsarAsodRBS -agrD-6xHis

FA-S1146

FA-S922 containing pOS1-PsarA- sodRBS -agrD
with 6x-His-tag on the C-terminal end
FA-S1008 containing pOS1-PsarA- sodRBS -agrD
with 6x-His-tag on the C-terminal end
FA-S995 containing pOS1-PsarA- sodRBS -agrD
with 6x-His-tag on the C-terminal end

Δ1984+ pOS1-PsarAsodRBS -agrD-6xHis
Δagr+ pOS1-PsarAsodRBS -agrD-6xHis
Δ1984 Δagr+ pOS1PsarA- sodRBS -agrD6xHis
Δ1984+1984+ pOS1PsarA- sodRBS -agrD6xHis

This work

FA-S1141
FA-S1142
FA-S1143

FA-S1147
FA-S1221
FA-S1265

FA-S982 containing pOS1-PsarA- sodRBS -agrD
with 6x-His-tag on the C-terminal end

FA-E1165

E. coli (LysY/Iq) containing pET-41b-AgrD

FA-S1297

LAC (AH-1263) containing pOS1-PsarA- sodRBS 6xHis with a 45 amino acid linker before agrDcmyc
FA-S922 containing pOS1-PsarA- sodRBS -6xHis
with a linker before agrD-cmyc

FA-S1298

sodRBS -6xHis

FA-S1299

FA-S982 containing pOS1-PsarAwith a linker before agrD-cmyc

FA-S1300

FA-S1008 containing pOS1-PsarAwith a linker before agrD-cmyc

FA-S1301

FA-S995 containing pOS1-PsarAwith a linker before agrD-cmyc

sodRBS -6xHis

sodRBS -6xHis

This work
This work

This work

This work
This work
This work
This work

WT+ pOS1-PsarAsodRBS -6xHis-linkagrD
Δ1984+ pOS1-PsarAsodRBS -6xHis-linkagrD
Δ1984+1984+ pOS1PsarA- sodRBS -6xHislink-agrD
Δagr+ pOS1-PsarAsodRBS -6x-His-linkagrD
Δ1984 Δagr+ pOS1PsarA- sodRBS -6xHislink-agrD

This work
This work
This work
This work
This work

Table 1. List of strains used in this study.

Molecular genetics techniques.
To isolate genomic DNA from S. aureus, cultures were grown overnight in 5 mL
TSB at 37°C with shaking at 200 rpm. 1.5 mL of bacteria were then pelleted by
centrifugation and resuspended in 200 μL of TSM buffer (50 mM Tris, 0.5 M Sucrose, 10
mM MgCl2 (pH 7.5)) and 2.5 μL of a lysostaphin (Ambi Products) stock for a final
concentration of 25 μg/mL. Samples were mixed and incubated at 37°C for 15 minutes to
digest the cell wall of S. aureus. After this treatment the bacteria were pelleted by
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centrifugation at 14000 rpm for 5 minutes, supernatants were discarded, and the genomic
DNA was isolated using a Wizard Genomic DNA purification kit (Promega). Polymerase
chain reaction (PCR) was performed in a Flexid Mastercycler (eppendorf) using Phusion
High-Fidelity DNA Polymerase (New England Biolabs) or GoTaq DNA Polymerase
(Promega) and dNTPs (Quanta Biosciences). For all PCR reactions oligonucleotides were
ordered from Eurofins (see Table 2). Electrophoresis of DNA samples was performed in
0.8% agarose (Amresco) gels. Digestions were performed using restriction
endonucleases: XhoI, BamHI, EcoRI, KpnI, SacI and PstI (New England Biolabs)
following the manufacturer’s suggested protocols and digested plasmids were treated
with Shrimp Alkaline Phosphatase (Amresco). Following digestion, ligations were set up
using T4 DNA Ligase (New England Biolabs) and were incubated in an eppendorf
ThermoMixer at 16°C overnight. When necessary, PCR purifications and DNA gel
extractions were carried out using QIAGEN QIAquick kits.
Name

Sequence

1984-1 KpnI
1984-2

CCC-GGTACC (KpnI)-CCATAAATGATAAACCTCCAT
GTGTGATTCGTTTTTTTTATTA-GGCGCCCATAATTTTCCTCCAAATATT
AATATTTGGAGGAAAATTATG-GGCGCCTAATAAAAAAAACGAATCACAC
CCC-GAGCTC (SacI)-ATTTTTAGCCTTGGCAAATG
GGCGGATCCAGCACTATCAGTTAAAACAAT
GGCGAATTCACAAGAAGATAATAAGAAAAG
ATAT-GGATCC(BamHI)-ATGTTAAAATATTAAATACAAATT
AAATAAGTTAAATAATGTATT-GTGATGGTGATGGTGATGCATTTTAAGTCCTCCTTAATA
TATTAAGGAGGACTTAAAATG-CATCACCATCACCATCACAATACATTATTTAAACTTATTT
ATAT-GAATTC(EcoRI)-TTATTCGTGTAATTGTGTTAA
ATAT-GAATTC(EcoRI)
TTAGTGATGGTGATGGTGATGTTCGTGTAATTGTGTTAATTC
ATAT- CTCGAG (XHOI)-ATGCATCACCATCACCATC
ATAT-GAATTC (EcoRI)-TTATTCGTGTAATTGTGTTAAT
ATAT-CTCGAG (XHOI)-ATGAATACATTATTTAACTTATTT

1984-3
1984-4 SacI
37F
37R
agrB-F
agrB-R
agrD-F
agrD-R
agrD-6xHis-R
6xHis-agrD-F XHOI
6xHis-agrD-R EcoRI
agrD-6xHis-F-XhoI
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agrD-6xHis-R-EcoRI
6xHis-agrD-R-BamHI
agrD-6xHis-R-BamHI
PHELP-agrD-SOE1-PstI
PHELP-6xHis-agrDSOE2
PHELP-6xHis-agrDSOE3
PHELP-6xHis-agrDSOE4-BamHI
PHELP-agrD-6xHisSOE2
PHELP-agrD-6xHisSOE3
PHELP-agrD-6xHisSOE4-BamHI
Psara- sodRBS -SOE1PstI
Psara- sodRBS -6xHisagrD-SOE2
Psara- sodRBS -6xHisagrD-SOE3
Psara- sodRBS -6xHisagrD-SOE4-EcoRI
Psara- sodRBS -agrD6xHis-SOE2
Psara- sodRBS -agrD6xHis-SOE3
Psara- sodRBS -agrD6xHis-SOE4-EcorI
UNI- Psara- sodRBS SOE1-PstI
Psara- sodRBS -6xHisLinker-agrD-SOE2
Psara- sodRBS -6xHisLinker-agrD-SOE3
Psara- sodRBS -6xHisLinker-agrD-SOE4EcorI

ATAT-GAATTC(ecorI)-TTAGTGATGGTGATGGTGA
ATAT-GGATCC(BamHI)- TTATTCGTGTAATTGTGTTAAT
ATAT-GGATCC(BamHI)- TTAGTGATGGTGATGGTGA
ATAT-CTGCAG(PSTI)-ATCCCATTATGCTTTGGCA
GATGGTGATGGTGATGCAT-GGGTTTCACTCTCCTTCTA
TAGAAGGAGAGTGAAACCC-ATGCATCACCATCACCATC
ATAT-GGATCC(BamHI)-TTATTCGTGTAATTGTGTTAAT
AAATAAGTTAAATAATGTATTCAT-GGGTTTCACTCTCCTTCTA
TAGAAGGAGAGTGAAACCC-ATGAATACATTATTTAACTTATTT
ATAT-GGATCC(BamHI)-TTAGTGATGGTGATGGTGA
ATAT-CTGCAG(pstI)-CTGATATTTTTGACTAAACCA
GATGGTGATGGTGATGCAT-AAATAATCATCCTCCTAAGG
CCTTAGGAGGATGATTATTT-ATGCATCACCATCACCATC
ATAT-GAATTC(ecorI)-TTATTCGTGTAATTGTGTTAAT
AAATAAGTTAAATAATGTATTCAT-AAATAATCATCCTCCTAAGG
CCTTAGGAGGATGATTATTT-ATGAATACATTATTTAACTTATTT
ATAT-GAATTC(ecorI)-TTAGTGATGGTGAATGGTGA
ATAT-CTGCAG(Pst1)-CTGATATTTTTGAC
GATGACCAGAACCACTAGT-CATAAATAATCATCCTCCTAAGGT
ACCTTAGGAGGATGATTATTT-ATGACTAGTGGTTCTGGTCATC
ATAT-GAATTC (ecorI)-CTCGAG(XhoI)-CAGATCTTCTTCA

Table 2. List of Oligonucleotides

To isolate plasmids from S. aureus, 5 mL overnight cultures of bacteria were
grown in TSB at 37°C with shaking at 200 rpm. The next day, bacteria were pelleted by
centrifugation at 4200 rpm for 15 minutes and then resuspended in 400μl of TSM buffer
and 20 μl of lysostaphin stock solution for a final concentration of 0.1 mg/mL of
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lysostaphin. Samples were incubated for 10 minutes at 37°C. After digesting the cell wall
with lysostaphin, the bacteria were centrifuged at 13000 rpm for 2 minutes and
supernatants were discarded. A Qiagen miniprep kit was used to isolate plasmid DNA.
DNA was eluted with sterile water in all cases. DNA sequencing was performed by
Genscript.
E. coli competent cell preparation.
To prepare chemically competent E. coli, 3 mL overnight cultures were grown in
LB at 37°C with shaking at 200 rpm. The next day, sub-cultures were inoculated at a
1:55 dilution in 110 mL fresh LB. Bacteria were incubated at 37°C with shaking at 200
rpm until the cultures reached mid-logarithmic phase, OD600 nm 0.3 -0.4 (about 2.5
hours). Upon reaching logarithmic growth phase, the culture was distributed into four 50
mL conical tubes and chilled on ice for 10 minutes. Samples were then centrifuged at
4000 rpm for 5 minutes at 4°C, supernatants were discarded, and pellets were
resuspended in 10 mL of Transfomation Buffer 1 (30 mM KOAc, 100 mM RbCl2 , 10
mM CaCl2 , 50 mM MnCl2, 15% Glycerol ( pH 5.8)(Amresco)). Cells were incubated on
ice for 10 minutes and then centrifuged at 4000 rpm for 5 minutes at 4°C, supernatants
were discarded, and pellets were resuspended in 1 mL of filter-sterilized Transformation
Buffer 2 (10 mM MOPS, 10 mM RbCl2, 75 mM CaCl2, 15% Glycerol (pH
6.5)(Amresco)). Once resuspended, cells were aliquoted into 1.5 mL microcentrifuge
tubes and stored at -80°C.
E. coli heat transformation.
Chemically competent cells were thawed on ice before being mixed with 5 μL of
a ligation mixture and incubated on ice for 30 minutes. After 30 minutes, cells were heat
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shocked for 45 seconds at 42°C and immediately put back on ice for an additional 2
minutes. 250 μL of sterile SOC medium [2% tryptone (Amresco), 0.5 % yeast extract
(Amresco), 0.05 % NaCl (Amresco), 10% 250 mM KCl (Amresco), and 20% filtersterilized 1 M glucose solution (pH 7.0)] was added to the transformation mixture and
incubated at 37°C, with shaking at 200 rpm, for 2 hours. Following this incubation, 50 μL
of competent cells were spread onto LB plates containing any required antibiotics for
selection and placed at 37°C overnight. Colonies were then screened for antibiotic
resistance and the presence of the transformed plasmid.
Preparation of S. aureus electrocompetent cells.
S. aureus cultures were grown overnight in 5 mL of TSB with any required
antibiotics at 37°C with shaking at 200 rpm. The next day, the cultures were diluted
1:100 in 30 mL of fresh TSB and incubated for 3 hours until reaching mid-logarithmic
phase. After 3 hours the bacteria were pelleted by centrifugation at 8000 rpm for 10
minutes at 4°C and the supernatants were discarded. The pellet was resuspended in 30
mL of ice-cold 10% glycerol (Amresco) and then centrifuged and washed two additional
times, first in 30 mL of 10% glycerol and then 15 mL of 10% glycerol. After a final spin,
cells were resuspended in 3 mL 10% glycerol and aliquots were stored in 1.5 mL
microcentrifuge tubes at -80°C until needed.
S. aureus transformation.
To transform plasmids into S. aureus strains via electroporation, 3 μL to 10 μL of
purified plasmid was incubated with 50 μL of competent S. aureus cells that were thawed
at room temperature for 5 minutes. The mixture was incubated at room temperature for
30 minutes before being transferred to a sterile 2 mm electropoation cuvette (VWR).
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Samples were electroporated (pulsed at 1800 V, 10 μF, and 600 Ω) in a GenePulser Xcell
BIORAD Electroporator. Immediately following electroporation, 750 μL of fresh TSB
was added to the samples and cells were then transferred to microcentrifuge tubes and
incubated at 30°C. Following recovery, either 100 μL of cells were spread on TSA plates
or samples were centrifuged at 10000 rpm for 2 minutes and all but 100 μL were
removed from the supernatant and the cells were resuspended in 100 μL followed by
spreading on TSA plates. Plates were supplemented with antibiotics as needed for
selection and subsequently incubated at 30°C or 37°C overnight. Occasionally, samples
required 24-48 hours for bacterial growth to be observed. Colonies were then screened
for antibiotic resistance and plasmid presence.
Bacteriophage-mediated generalized transduction.
Transduction was used to stably integrate plasmids, as well as generate marked
mutations within the S. aureus chromosome. S. aureus specific bacteriophages ϕ11 or
80α were used in this study. Donor strains were grown overnight in 3 mL of TSB/LB
(1:1) supplemented with 5 mM calcium chloride (CaCl2 )(Amresco) and 5 mM
magnesium sulfate (MgSO4)(Amresco) at 37°C with shaking at 200 rpm. The next day,
overnight cultures were diluted 1:100 in 10 mL of fresh TSB/LB (1:1), again
supplemented with 5 mM CaCl2 and 5 mM MgSO4. Samples were grown for about 3
hours at 37°C with shaking at 200 rpm until the cultures reached an optical density (OD
600 nm) between 0.3 and 0.9. To package the donor DNA into the phage, 100 μL of 10fold serial dilutions (10-1 to 10-10) of bacteriophage stock in TMG (10 mM Tris pH 7.5, 5
mM MgCl2, 0.01% gelatin (v/v)) were added to 15 mL conical tubes and incubated with
500 μL of the donor S. aureus culture. The phage-bacteria mixture was gently vortexed
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and incubated at room temperature for 30 minutes. 2.5 mL of melted and cooled CY Top
agar (Casamino acids 5 g/L, Yeast Extract 5 g/L, glucose 5 g/L, NaCl 6 g/L, 7.5 g/L agar)
supplemented with 5 mM CaCl2 and 5 mM MgSO4 was quickly added to each tube. The
mixture of CY top agar, bacterial suspension, and the phage dilutions were immediately
poured onto TSA plates. Plates were incubated overnight at 30°C. The following day,
phage were harvested from two to three plates with confluent plaques. The top agar was
scraped from each of these plates using a sterile scoopula and combined into one 50 mL
conical tube. 2 mL of TMG buffer per plate was added to the tube and vortexed
extensively. To separate the agar from the bacteriophage, the tube was centrifuged for 15
minutes at maximum speed. The supernatant was collected and filter sterilized once
through a 0.45 μm syringe filter and twice through a 0.22 μm syringe filter.
Bacteriophage stocks were stored at 4°C.
To transduce plasmids and marked mutations, recipient strains were first grown
overnight in 20 mL of TSB/LB (1:1) supplemented with 5 mM CaCl2 at 37°C. Samples
were then centrifuged for 15 minutes at max speed, supernatants were discarded, and the
pellets were resuspended in 3 mL of CY medium (casamino acids 5 g/L, yeast extract 5
g/L glucose 5 g/L NaCl 6 g/L) supplemented with 5 mM CaCl2. Next, 4 conditions were
set up with bacteria alone or 10-fold serial dilutions of bacteria infected with 100 μL of
bacteriophage stock packaged with donor DNA. Tubes were mixed by inverting every ten
minutes for 30 minutes at room temperature. Next, 40 mM sodium citrate was added to
each tube and incubated at room temperature for 30 minutes, again mixing every 10
minutes. Tubes were centrifuged at maximum speed for 5 minutes and washed twice in
500 μL of CY medium supplemented with 40 mM sodium citrate. After one final
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centrifugation, samples were resuspended in 200 μL of CY medium supplemented with
40 mM sodium citrate and spread on CY agar or TSA plates containing 10 mM sodium
citrate and any antibiotics necessary for selection. Plates were placed at 37°C overnight
and potential transductants were screened for antibiotic resistance and acquisition of
desired mutations.
Generation of a SAUSA300_1984 in-frame deletion mutant.
A SAUSA300_1984 in-frame deletion mutant was generated using a temperaturesensitive mutagenesis vector known as pIMAY (55). Two fragments that correspond to
~500 base pair regions of sequence homology immediately upstream and downstream of
1984 were amplified. Oligonucleotides 1984-1 and 1984-2 were used to amplify the
region upstream of 1984, while oligonucleotides 1984-3 and 1984-4 were used to amplify
the region downstream of 1984 (Table 2). These fragments were joined by splicing by
overlap extension (SOEing) PCR using oligonucleotides 1984-1 and 1984-4 and
subcloned into the multi-cloning site of pIMAY using restriction endonucleases KpnI and
SacI followed by ligation. pIMAY is a temperature sensitive plasmid that replicates at
28°C, but cannot replicate at 37°C and integrates into the S. aureus genome based upon
recognition of overlap with the cloned regions of homology described above. Integration
of pIMAY is selected on chloramphenicol plates as pIMAY contains a highly expressed
chloramphenicol resistance gene. Once pIMAY-1984 was transformed into LAC (AH1263) by electroporation cultures were grown at 37°C in the presence of
chloramphenicol, causing the plasmid to insert into the chromosome by recombination
either upstream or downstream of 1984. To facilitate a second recombination event that
would promote plasmid excision and gene deletion, cultures were shifted to 28°C in the
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absence of antibiotic selection. Following plasmid excision, inducible counter-selection
with anhydrous tetracycline (AnTet) was used to eliminate S. aureus still harboring
pIMAY by plating on medium containing AnTet. AnTet induces the expression of a secY
antisense RNA transcript under control of the Pxyl/tetO promoter. After curing the plasmid,
potential mutants were screened by PCR using oligonucleotides 1984-1 and 1984-4
which flank the deleted region. The PCR products were run on an agarose gel and
evaluated for a reduction in product length corresponding to deletion of the 1984 gene.
Generation of 1984 complementation strain.
A single copy chromosomal complementation strain was constructed using the
pJC1112 vector, which stably integrates into a neutral site of the chromosome, driving
1984 expression under its native promoter (53). This construct was generated by PCR
using oligonucleotides 37F and 37R (Table 2). The resulting amplicon was then
subcloned into the pJC1112 vector using the EcoRI and BamHI restriction sites. This
construct was then transformed into the DH5α E. coli followed by electroporation into
the RN9011 where the plasmid integrates at the SapI1 site. The integrated
complementation vector was then transduced into Δ1984. Complementation was
confirmed by PCR and sequencing.
Construction of Δagr::tet mutants.
A marked deletion mutation of agrBDCA was moved from a LAC background
into plasmid cured LAC (AH-1263) as well as Δ1984 by bacteriophage-mediated
transduction, using phage 80α, as described above.
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Construction of P3 reporter strains.
The pDB59 plasmid described in Table 1 contains the P3 promoter of the Agr
system driving the expression of GFP. The P3 promoter is induced when AgrA is
activated by AIP-bound AgrC. Therefore, the plasmid monitors induction of the Agr
system by AIP (54). The pDB59 plasmid was isolated from E. coli and passaged through
RN4220. The plasmid was then electroporated into WT, Δ1984, and Δagr::tet.
Construction of 6x-histidine-tagged AgrD expression vectors.
Construction of 6x-histidine-tagged AgrD with expression under its native
promoter. We first constructed a series of 6x-histidine-tagged expression vectors using
pJC1112 (used for complementing 1984). These constructs drive agrD expression under
its native promoter and therefore included the agrB gene. Constructs with a N-terminal
6x-histidine-tagged AgrD as well as a construct with a C-terminal 6x-histidine-tagged
AgrD were created. For the N-terminal 6x-histidine-tagged construct (pJC1112-agrB6xHis-agrD), two fragments corresponding to agrB and agrD were amplified.
Oligonucleotides agrB-F and agrB-R were used to amplify agrB, while oligonucleotides
agrD-F, which includes a 6x-histidine-tag coding sequence, and agrD-R were used to
amplify the N-terminal 6x-histidine-tagged agrD. These fragments were joined by
splicing by overlap extension (SOEing) PCR using oligonucleotides agrB-F and agrD-R.
For the C-terminal tagged (pJC1112-agrBD-6xHis) construct, oligonucleotides agrB-F
and agrD-6xHis-R, which includes a 6x-histidine-tag coding sequence were used. Once
6x-histidine-tagged agrBD amplicons were generated they were cloned into pJC1112
using EcoRI and BamHI restriction sites. Constructs were transformed into DH5α,
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electroporated into RN9011, and transduced into wild type, Δ1984, Δ1984+1984, and
Δagr as described above.
Construction of inducible expression vector of 6x-histidine-tagged AgrD. All
further 6x-His-tagged AgrD expression vectors used a pOS1 vector (56), which is a
multicopy plasmid used to overcome issues of limited detection due to low protein
abundance. Two constructs were created using a hemin inducible promoter, Phrt, to drive
expression of the N- or C- terminal 6x-histidine-tagged AgrD. The N-terminal tagged
AgrD construct was PCR amplified from the pJC1112-agrB-6xHis-agrD construct as a
template using oligonucleotides XhoI-6xHis-AgrD and 6xHis-AgrD-EcoRI. The Cterminal tagged AgrD construct was amplified using pJC1112-agrBD-6xHis as a template
and oligonucleotides XhoI-AgrD-6xHis and AgrD-6xHis-EcorI. Once cloned into the
pOS1-Phrt vector using the XhoI and EcoRI restriction sites, the constructs were
transformed into DH5α, electroporated into RN4220, and then electroporated into wild
type, Δ1984, Δ1984+1984, and Δagr as described above.
Construction of constitutively expressed 6x-histidine-tagged AgrD driven by
Plgt. Similarly, both N and C-terminal 6x-histidine-tagged constructs were cloned into
pOS1 under control of the Plgt promoter, which is constitutive. For the N-terminal 6xhistidine-tagged construct the pJC1112-agrB-6xHis-agrD was used as the template in a
PCR with oligonucleotides 6xHis-agrD-F-XHOI and 6xHis-agrD-R-BamHI. The Cterminal 6x-histidine-tagged construct used the pJC1112-agrBD-6xHis as the template
for a PCR reaction using oligonucleotides agrD-6xHis-F-XhoI and agrD-6xHis-RBamHI. These amplicons were then cloned into the XhoI and BamHI restriction sites of
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the pOS1-Plgt vectors and transformed into DH5α, electroporated into RN4220, and then
electroporated into wild type, Δ1984, Δ1984+1984, and Δagr as described above.
Construction of constitutively expressed 6x-histidine-tagged AgrD driven by
PHELP. Another vector was generated to drive expression of 6x-His-AgrD under the
control of the PHELP promoter derived from pIMAY. PHELP is a constitutive promoter (55).
PHELP was isolated from pIMAY using PCR and the fragment was then joined with the
sequence for either the N-terminal or C-terminal 6x-histidine-tagged AgrD by SOEing
PCR. For the N-terminally tagged AgrD construct PCR was performed using pIMAY as a
template with oligonucleotides PHELP-agrD-SOE1-PstI and PHELP-6xHis-agrD-SOE2
while the pOS1-Phrt-agrD-6xHis was used as template for a PCR reaction with
oligonucleotides PHELP-6xHis-agrD-SOE3 and PHELP-6xHis-agrD-SOE4-BamHI. The
resultant amplicons were then spliced together by SOEing PCR using olignoculeotides
PHELP-agrD-SOE1-PstI and PHELP-6xHis-agrD-SOE4-BamHI. Similarly, the C-terminal
construct was generated by PCR using pIMAY as a template with oligonucleotides
PHELP-agrD-SOE1-PstI and PHELP-agrD-6xHis-SOE2, while pOS1-Phrt-6xHis-agrD was
the template for a second PCR with oligonucleotides PHELP-agrD-6xHis-SOE3 and PHELPagrD-6xHis-SOE4-BamHI. These fragments were then spliced together by SOEing PCR
and cloned into pOS1 using the PstI and BamHI restriction sites.
Construction of 6x-histidine-tagged AgrD overexpression vectors. Additional
overexpression plasmids were generated using the PsarA promoter, a highly transcribed
promoter linked to the sod ribosomal binding site, an optimal ribosome binding site for S.
aureus. These plasmids were constructed using SOEing PCR in a similar manner to the
pOS1-PHELP constructs described above. For the N-terminal 6x-histidine-tagged AgrD,
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PsarA-sodRBS was amplified using oligonucleotides PsarA- sodRBS -SOE1-PstI and PsarasodRBS -6xHis-agrD-SOE2. pOS1-Phrt-6xHis-agrD was used as template along with
oligonucleotides Psara- sodRBS -6xHis-agrD-SOE3 and Psara- sodRBS -6xHis-agrD-SOE4EcoRI. These amplicons were then spliced together using primers PsarA- sodRBS -SOE1PstI and Psara- sodRBS -6xHisagrD-SOE4-EcoRI and the resultant product was cloned into
pOS1 using the PstI and EcoRI restriction sites. This plasmid was then transformed into
DH5α, electroporated into RN4220, and then electroporated into wild type, Δ1984,
Δ1984+1984, and Δagr as described above. The C-terminal 6x-histidine-tagged AgrD
construct under the transcriptional control of PsarA was generated in the same way. pOS1Phrt-agrD-6xHis was used as the agrD template in a PCR reaction with oligonucleotides
Psara- sodRBS -agrD-6xHis-SOE3 and Psara- sodRBS -agrD-6xHis-SOE4-EcorI and PsarA
was amplified using primers PsarA-sodRBS-SOE1-PstI and Psara- sodRBS -agrD-6xHisSOE2. Again, a SOEing PCR was performed to splice these amplicons together using
primers PsarA- sodRBS -SOE1-PstI and Psara- sodRBS -agrD-6xHis-SOE4-EcorI. This
product was cloned into pOS1 using the PstI and EcoRI restriction sites, transformed into
DH5α, electroporated into RN4220, and then electroporated into wild type, Δ1984,
Δ1984+1984, Δagr and Δ1984Δagr as described above. The strains containing pOS1PsarA- sodRBS -agrD-6xHis are referred to as WT+C, Δ1984+C, Δ1984+1984+C,
Δagr+C, and Δ1984Δagr+C.
Construction of N-terminal 6x-histidine-tagged AgrD with a linker region
construct. Lastly, troubleshooting issues with the detection of N-terminal 6x-histidinetagged AgrD led us to generate an expression vector that used pOS1-PsarA- sodRBS as a
promoter, but we added a linker region between the 6x-histidine-tag and the N-terminal
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end of agrD. For these purposes the 6x-histidine-tag, an S- tag, agrD, and c-myc were
amplified from an E. coli AgrD expression strain. pOS1-PsarA- sodRBS -agrD-6xHis was
used as a template for a PCR using oligonucleotides UNI- Psara- sodRBS -SOE1-PstI and
Psara- sodRBS -6xHis-Linker-agrD-SOE2. pET-41b-agrD was used as a template for a
PCR using oligonucleotides Psara- sodRBS -6xHis-Linker-agrD-SOE3 and Psara- sodRBS 6xHis-Linker-agrD-SOE4-EcorI. These amplicons were then used in a SOEing PCR with
oligonucleotides UNI- Psara- sodRBS -SOE1-PstI and Psara- sodRBS -6xHis-Linker-agrDSOE4-EcorI. The resulting product was then cloned into the multi-cloning site of pOS1
using the PstI and EcoRI restriction sites, transformed into DH5α, electroporated into
RN4220, and then electroporated into wild type, Δ1984, Δ1984+1984, Δagr and
Δ1984Δagr as described above. The strains containing pOS1-PsarA- sodRBS -6xHis-linkeragrD are referred to as WT+N, Δ1984+N, Δ1984+1984+N, Δagr+N, and
Δ1984Δagr+N.
Whole cell lysate preparation.
5 mL of S. aureus strains were grown overnight at 37°C with shaking at 200 rpm.
Overnight cultures were diluted 1:50 in 20 mL of fresh medium and allowed to replicate
for an additional 8 hours at 37°C with shaking at 200 rpm. After 8 hours, the OD600 nm
was measured and samples were centrifuged at 4200 rpm for 15 minutes. Supernatants
were removed and the bacterial cell pellets were stored at -80°C until use. Pellets were
thawed on ice and resuspended in 250 μL of sterile PBS, 250 μL of PBS supplemented
with 1 M NaCl (Amresco), or 250 μL of PBS supplemented with 1 M NaCl and 6 M
Urea (VWR). The resuspended bacteria were then added to screw cap microcentrifuge
lysing tubes (Fisher Scientific) containing 250 μL 0.1 mm glass cell disruption beads
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(Scientific Industries, Inc.). Cells were lysed using a Fast Prep-24 5G (MP Biomedicals).
Cells were disrupted at speed 5.0 for 20 seconds, allowed to recover on ice for 5 minutes,
and then disrupted a second time at speed 4.5 for 20 seconds. Samples were then either
(a) centrifuged at maximum speed for 15 minutes at 4°C and 45 μL of supernatants were
collected and boiled for 10 minutes with 15 μL of 6x SDS sample buffer (0.375 M Tris
pH6.8, 12 SDS, 60% glycerol, 0.6 M DTT, 0.06% bromophenol blue), or (b) 50 μL of 6x
SDS Sample buffer was added directly to lysed cells and boiled for 10 minutes. After
boiling, the tubes were centrifuged at maximum speed for 15 minute at 4°C and
supernatants were collected. These two preparations allowed for the collection of a
soluble cell lysate fraction and total (soluble and insoluble) proteins. Samples were stored
at -20°C for no longer then a few days.
Exoprotein preparations.
S. aureus strains were grown at 37°C with shaking at 200 rpm overnight.
Overnight cultures were diluted 1:50 in fresh medium and allowed to grow 8 hours to
stationary phase at 37°C with shaking at 200 rpm. After 8 hours, the OD600 nm was
measured and samples were centrifuged at 4200 rpm for 15 minutes. 1.3 mL of
supernatants were collected in 1.5 mL eppendorf tubes and cooled on ice for
approximately 30 minutes. Next, 150 μl of 100% tri-chloro acetic acid (TCA) was added
to the samples and the tubes were mixed by inversion followed by overnight incubation at
4°C. The next day samples were centrifuged at 4°C for 15 minutes at maximum speed
and supernatants were removed and discarded. Samples were incubated in 1 mL of 100%
ethanol (Decon Laboratories Inc.) for 30 minutes at 4°C followed by another 15 minute
spin at 4°C at maximum speed. Supernatants were again discarded and pellets dried at
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room temperature for about one hour. Pellets were then dissolved in TCA-SDS sample
buffer (0.5 M Tris-HCL buffer, 4%SDS mixed 1:1 with 2x SDS Sample buffer) and
boiled for 10 minutes before storage at -20°C.
Affinity-based enrichment of 6x-histidine-tagged AgrD.
S. aureus strains were grown at 37°C with shaking at 200 rpm overnight and then
diluted 1:50 in fresh medium and let grow 8 hours at 37°C with shaking at 200 rpm. After
8 hours, the OD600 nm was measured and samples were centrifuged at 4200 rpm for 15
minutes. Supernatants were removed and the pellets (bacterial cells) were stored at -80°C.
Pellets were thawed on ice and resuspended in 250μl sterile PBS supplemented with 1M
NaCl and 1mM phenylmethanesulfonyl floride (PMSF) (Acros organics). The suspended
bacteria were then added to screw cap microcentrifuge lysing tubes (Fisher Scientific)
containing 250 μL 0.1 mm glass cell disruption beads (Scientific Industries, Inc.). Cells
were lysed using a Fast Prep-24 5G (MP Biomedicals) by two disruption steps. First,
cells were disrupted at speed 5.0 for 20 seconds and allowed to recover on ice for 5
minutes. Then cells were disrupted a second time at speed 4.5 for 20 seconds. Lysates
were centrifuged at maximum speed for 15 minutes at 4°C. Supernatants were then
incubated with Ni-NTA superflow nickel resin (Qiagen) for 1 hour at room temperature
on a rotisserie. Following incubation, the resin was centrifuged at 3000 rpm for 3 min and
supernatants were discarded. The resin was then washed six times in PBS with 1M NaCl
and 25 mM Imidazol (Amresco). After the last wash, the resin was resuspended in 6x
SDS buffer and boiled for 10 minutes followed by centrifugation at 3000 rpm for 3
minutes, removal of supernatant, and storage at -20°C.
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Immunoblot for virulence factors.
Wild type, Δ1984, Δ1984+1984, and Δagr strains were grown in 5 mL of RPMI
for eight hours at 37°C with shaking at 200 rpm and supernatants were collected for TCA
precipitation as described above. Once prepared, protein samples were normalized based
on OD600nm and were separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) in 12% polyacrylamide gels at 120 volts in a Quadra MiniVertical PAGE/Blotting System (CBS Scientific). Resolved proteins were then
transferred from polyacrylamide gels to 0.45 μm PVDF membranes (Immobilon, Roche)
at 200 V for 1 hr. After transfer, membranes were stored overnight in PBST (0.1% Tween
-20 (Amresco) in PBS (Corning)) at 4°C. Membranes were then blocked in PBST with
1% Bovine Serum Albumin (BSA) (Amresco) for 1 hour while rocking. Following this
blocking step, rabbit anti-LukA and rabbit anti-LukE antibodies (57), at a 1:7500 dilution
in PBST supplemented with 1% BSA, were incubated with the membranes and allowed
to rock for 1 hour. Although these antibodies recognize LukAB and LukED, we are also
able to detect Protein A due to its binding of the FC region of antibodies. Following
incubation with the primary antibodies, membranes were washed three times in PBST for
15 minutes and goat anti-rabbit IgG (H+L) HRP conjugate (Thermo) was then added at a
1:400 dilution in PBST with 1% BSA for 1 hour while rocking. After this incubation the
membranes were washed 3 more times in PBST for 15 minutes each and immunoblot
images were captured on FluorChem System (Protein Simple) using SuperSignal West
Pico Chemiluminiscent Substrate (Thermo).
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Immunoblot of cleavage events.
Strains containing plasmids with either the C-terminal or N-terminal 6x-histidinetagged agrD were grown in 20 mL of RPMI for eight hours at 37°C with shaking at 200
rpm and supernatants and cell lysates were processed as described above. Protein samples
were either normalized to growth based on OD600nm or based on band intensity in prior
immunoblots. Proteins were separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) in 12% polyacrylamide gels at 120 volts in a Quadra MiniVertical PAGE/Blotting System (CBS Scientific) or by Tricine-SDS-PAGE (Schagger
2006) in 21% polyacrylamide gels with 6M urea at 200 to 300 volts in a HoeferTM SE 600
series electrophoresis apparatus. Resolved proteins were then transferred from
polyacrylamide gels to 0.20 μm PVDF membranes (Immobilon, Roche) at 70 V for 75
minutes in a Quadra Mini-Vertical PAGE/Blotting System (CBS Scientific). Immediately
following transfer, membranes were fixed in a 4% paraformaldhyde (Alfa Aesar) solution
for 30 minutes at room temperature. Membranes were then washed for 20minutes in
PBST and blocked overnight in PBST with 5% Milk (Roundy’s) at 4°C with rocking.
The next day the membranes were washed in PBST 3 times for 20 minutes. Mouse anti6x-histidine antibody (Abcam) at a 1:3000 dilution in PBST with 1% BSA was incubated
with each membrane for 1 hour at room temperature followed by three 20 minute washes
with PBST. Secondary goat anti-mouse IgG (H+L) HRP conjugate (Thermo) was then
added at a 1:400 dilution in PBST with 1% BSA for 1 hour while rocking followed by
four washes for 20 minutes each in PBST. Immunoblot images were captured on BioDot
blue autoradiography film (Dot Scientific) using SuperSignal West Pico
Chemiluminiscent Substrate (Thermo).
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Membrane Fraction preparation and application of purified AgrD.
Strains containing the C-terminal 6x-histidine-tagged AgrD were grown overnight
in TSB at 37°C with shaking at 200 rpm. The next morning cultures were diluted 1:100 in
50 mL of fresh medium and grown for 6 hours at 37°C with shaking at 200 rpm.
Samples were then centrifuged at max speed for 15 minutes, the supernatants were
discarded and the bacterial pellets stored at -80°C overnight. The next day, the pellets
were thawed on ice before being resuspended in 4 mL of Birnboim solution 1 (50mM
glucose, 10 mM EDTA, 25 mM Tris-HCl (pH 8.0)) and 200μl of lysostaphin. Samples
were incubated for at least 30 minutes at 37°C with shaking at 200 rpm. After incubation,
cells appeared lysed and samples were cooled to approximately 4°C on ice. Once cooled,
samples underwent 3 rounds of sonication for 30 seconds each at 20% power with 5
minutes of cooling on ice between rounds of sonication. Following sonication, samples
went through 3 freeze thaw cycles in a dry ice-ethanol bath and one additional round of
sonication. Intact cells were then removed with a low speed centrifugation at 500 g for 3
min at 4°C. Supernatants were collected and placed in thick-walled microfuge tubes and
centrifuged at 50,000 g for 45 minutes at 4°C. After centrifugation, the supernatant
containing the soluble fraction was discarded and the pellet containing the membrane
fraction was resuspended in 300 μl of membrane extraction buffer (50mM HEPES (pH
7.4), 125mM NaCl, 5% v/v glycerol, and 1% (W/W) dodecyl maltoside (DDM)).
Samples were then moved to new conical tubes and underwent a final 2 rounds of
sonication for 1 second each at 10% power using a microprobe. Samples containing S.
aureus membranes were placed on a rocker at 4°C for 1 hour and then aliquoted and
stored at -20°C.
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Alex Argianas purified 6x-histidine-tagged AgrD using affinity purification and
Fast Protein Liquid Chromatography (FPLC), and samples were stored at -20°C.
Membrane fractions as well as purified AgrD were thawed on ice and protein levels were
measured using PierceTM BCA Protein Assay Kit (Thermo Scientific). 50 μg of
membrane proteins were incubated with 1-3 μl of purified AgrD at 25°C for 90 minutes.
After incubation, 60 μl of 2x SDS buffer was added to each reaction and boiled for 10
minutes. Proteins were then separated by SDS-PAGE electrophoresis and transferred to a
0.2 μm PVDF membranes, and immunodetection of cleavage events was performed as
previously described.
Mass spectrometry.
Exoprotein preparations of wild type, Δ1984, Δ1984+1984, and Δagr strains were
collected as described above. Once prepared, protein samples were normalized based on
OD600nm and were separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) in 12% polyacrylamide gels at 120 volts in a Quadra MiniVertical PAGE/Blotting System (CBS Scientific). All equipment was washed with 4%
sodium dodecyl sulfate (SDS), deionized water, and ethanol before use and fresh buffer
was used. Gels were stained with coomassie blue, bands cut out with a cleaned razor
blade, and gel slices placed in snap closure tubes before being submitted for Mass
spectrometry (Alphalyse Pick n’ Post).
Macrophage cytokine Profiles.
Bacteria were grown overnight in triplicate in a 96-well round bottom plate
(Corning) in 150 μl of TSB at 37°C with shaking at 200 rpm. Samples were then diluted
in a 96-well round bottom plate 1:50 in 147 μl of fresh TSB and incubated for 8 hours at
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37°C with shaking at 200 rpm. Bacterial growth was assessed by reading the optical
density at 600 nm followed by centrifugation at 3700 rpm for 15 minutes. Supernatants
were collected and stored at -80°C. Primary bone marrow derived macrophages (BMDM)
were thawed and incubated at 37°C with 5% CO2 for 48 hours before seeding in a 96 well
plate at 65,000 cells per well. BMDM were allowed to rest overnight before being treated
with 10 μl of bacterial supernatant for 24 hours at 37°C at 5% CO2. After 24 hours 50 μl
of supernatants were collected and stored at -80°C. To assess cytokine levels, a BDTM
Cytometric Bead Array Mouse Soluble Protein Set and Soluble Protein Master Buffer Kit
were used. The manufacturer’s instructions were followed except each well contained 0.1
μl of each bead and 0.1 μl of each detection reagent for ten different cytokines.
AIP reporter assay.
Wild type, Δ1984, and Δagr strains containing pDB59 (described above) as well
as Δ1984+1984 were cultured overnight in TSB supplemented with Cm at 37°C with
shaking at 200 rpm. The next day samples were diluted 1:100 in fresh TSB and incubated
for 5 hours at 37°C with shaking at 200 rpm. Samples were centrifuged at 4,200 rpm for
10 minutes. Supernatants were collected and filter sterilized through a 0.45 nm syringe
filter and diluted 1:1 in fresh TSB. The pellets were then resuspended in 5 mL of the
conditioned medium and incubated an additional two hours. After this incubation, the
bacteria were washed in PBS twice and resuspended in 1mL of PBS. Samples were then
diluted two fold in PBS and aliquoted in triplicate into a flat bottom 96 well plate.
Bacterial optical density (OD600) as well as GFP levels (EX 395 nm, EM 509 nm), were
measured using an Omega plate reader. The data were normalized and displayed as
GFP/OD.
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Murine Infection models.
All animal experiments in this study were performed in an ABSL2 facility with
protocols approved by Loyola University of Chicago following the standards set forth by
the Institutional Animal Care and use Committee. For this study, 6 to 8 week old female
Swiss Webster mice (Envigo) were used and monitored daily after infection. Each
experiment contained cohorts of at least 4 mice and was repeated at least 3 times.
Murine Peritonitis infections. Cultures of wild type, Δ1984, Δ1984+1984, and
Δagr were inoculated from freshly isolated single colonies and grown with shaking at
37°C overnight. The next day, a 1:100 subculture into 15 mL of TSB was incubated at
37°C for 3 hours with shaking at 200 rpm. After incubation, cultures were then
centrifuged for 5 minutes at maximum speed and cell pellets were washed twice in 5 mL
of PBS. Once washed and resuspended in 5 mL of PBS, bacterial suspensions were then
normalized to an O.D. of approximately 1.1 (1 x 109 CFU/mL). Mice were infected
intraperitoneally with ~1x108 CFU of bacteria in 100 μl of PBS. Mice were monitored
daily and at approximately 72 hours post-infection were euthanized followed by
peritoneal lavage and isolation of kidneys. Tissues were aseptically isolated,
homogenized, spread onto TSA plates, and incubated overnight at 37°C in order to
enumerate CFU. Serum was also collected from each infected animal. Serum and
peritoneal lavage samples were then used for cytometric bead array to examine cytokine
levels as previously described. Immune cell populations were isolated from the kidney,
spleen, and peritoneal lavage and analyzed by flow cytometry for known markers of
phagocytic and lymphocytic cell populations and their activation status. For phagocytic
cell populations I used CD11b, Ly6G, CD11c, Dx5, CD14, CD206, IA/IE, and F4/80
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markers while I used CD44, CD11b, CD8, CD3, NK1.1, TCRγ/δ, CD4, and B220 for
lymphocyte populations.
Murine systemic infections. Cultures of wild type, Δ1984, Δ1984+1984, and
Δagr were inoculated from freshly isolated single colonies and grown with shaking at
37°C overnight. The next day, a 1:100 subculture into 15 mL of TSB was incubated at
37°C for 3 hours with shaking at 200 rpm. After incubation, cultures were then
centrifuged for 5 minutes at maximum speed and cell pellets were washed twice in 5 mL
PBS. Once washed and resuspended in 5 mL of PBS, bacterial suspensions were diluted
2mL into 8 mL of PBS and normalized to an O.D. of approximately 0.32-0.33 (1 x 108
CFU/mL). Mice were first deeply anesthetized with 2,2,2- tribromoethanol (Avertin;
Sigma) via intraperitoneal injection and then inoculated with 100 μl PBS containing
1x107 CFU of bacteria into the bloodstream via the retro-orbital venous plexus. Mice
were monitored daily until 96 hours post-infection, at which point they were euthanized
and kidney, heart, and liver were harvested. Tissues were aseptically isolated,
homogenized and spread onto TSA plates and incubated overnight at 37°C in order to
enumerate CFU. Additionally, serum was collected and immune cells were isolated for
flow cytometry analysis of immune cell recruitment as described above.
Murine skin and soft tissue infections. Cultures of wild type, Δ1984,
Δ1984+1984, and Δagr were inoculated from freshly isolated single colonies and grown
with shaking at 200 rpm at 37°C overnight. The next day, a 1:100 subculture in 15 mL of
TSB was incubated at 37°C for 3 hours with shaking. After incubation, cultures were
then centrifuged for 5 minutes at maximum speed and cell pellets were washed twice in 5
of mL PBS. Once washed and resuspended in 5 mL of PBS, bacterial suspensions were
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diluted 2mL into 8 mL of PBS and normalized with PBS to reach to an O.D. of
approximately 0.32-0.33 (1 x 108 CFU/mL) and mixed 1:1 with sterile Cytodex beads
(Sigma). Mice were first deeply anesthetized with 2,2,2- tribromoethanol (Avertin;
Sigma) via intraperitoneal injection. After anesthetization, mice flanks were shaved and
inoculated with 100 μl PBS containing 1x107 CFU of bacteria and Cytodex beads on the
right and left side by intradermal injection. Mice were monitored daily and at 72 or 120
hours post-infection mice were euthanized. Skin abscesses were collected, homogenized,
spread onto TSA plates, and incubated overnight at 37°C in order to enumerate CFU.
Skin homogenates and serum were also collected for cytometric bead array analysis for
cytokine levels, as previously described.
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CHAPTER THREE
EXPERIMENTAL RESULTS
Determine whether the function of 1984 is linked to Agr activity
Introduction. Over the past several decades, cases of both hospital-acquired and
community-acquired S. aureus infections have increased, resulting in over 300,000
hospitalizations and 11,000 deaths a year (2, 3). This rise in infection rates is thought to
be due to both increased incidence of antibiotic resistance among infectious isolates as
well as alterations in virulence factor gene expression, allowing more efficient immune
evasion. S. aureus uses complex and redundant regulatory systems to produce a diverse
array of cytotoxins and virulence factors that promote its survival. These same virulence
factor regulatory schemes allow S. aureus to evade the complex innate immune
surveillance mechanisms it encounters. For these reasons, it is important to understand
the mechanisms used by S. aureus to control virulence factor gene expression and
promote its pathogenesis.
Previous identification of a 1984 mutant during a transposon mutant library
screen. Deciphering the mechanisms that S. aureus uses to interact with cells of the
immune system will help us to understand how S. aureus evades critical host defense
strategies. To identify factors that positively or negatively modulate macrophage activity,
Dr. Alonzo conducted a screen using supernatants derived from an annotated transposon
mutant library of S. aureus. These supernatants were applied to murine bone marrow
39
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derived macrophages and cytokine production was examined by cytometric bead array.
Mutants were identified that either positively or negatively altered cytokine production to
a significant degree. One mutant that elicited a hyper-inflammatory macrophage response
contained a transposon insertion in the gene SAUSA300_1984. This mutant induced the
production of IL-1β at levels greater than two standard deviations from the mean induced
by all other mutants in the screen (Figure 3). Because only cell free supernatant was
applied to the macrophages, Dr. Alonzo hypothesized that the secreted factors from
1984::erm might be different from wild type S. aureus. Consistent with this hypothesis,
Dr. Alonzo has shown that 1984::erm does have an altered exoprotein profile that lacks
many proteins present in wild type supernatant (Figure 4). To begin to determine whether
1984 plays a role in pathogenesis, Dr. Alonzo used the 1984::erm transposon mutant in a
murine peritonitis model of infection. Dr. Alonzo enumerated the bacterial colony
forming units (CFUs) at three sites: the kidney, peritoneal cavity, and blood after 16
hours of infection (Figure 5). He found that the bacterial burden of 1984::erm was lower
than that of wild type S. aureus in each site (Figure 5). These data suggested that the
function of 1984 is critical for S. aureus survival during infection and supported further
study of the function of 1984.
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Figure 3. A 1984::erm transposon mutant elicits an enhanced IL-1β response in macrophages. Murine
bone marrow derived macrophages were incubated with supernatants derived from an S. aureus transposon
mutant library and IL-1β cytokine production levels were measured. Blue circles represent mutants that
elicited cytokine production by the macrophages greater than two standard deviations from the mean
induced by all other mutants. Pink circles represent 1984::erm and agrB::erm, respectively. Courtesy of
Dr. Alonzo.

Figure 4. Exoprotein profile of a mutant with a transposon insertion in 1984 is altered compared to
that of wild type S. aureus. Wild type and 1984::erm were grown in TSB for 9 hours at 37°C with shaking
at 200 rpm before supernatants were collected, processed, and resolved by SDS-PAGE. Gel stained with
coomassie. Courtesy of Dr. Alonzo.
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Figure 5. A 1984::erm mutant is attenuated in vivo. Mice were infected with 1x108 CFU of wild type S.
aureus or the transposon mutant using a peritoneal infection model and CFU were enumerated 16 hours
post infection in kidney, peritoneal lavage, and serum. Courtesy of Dr. Alonzo.

A Δ1984 mutant phenotypically mimics a Δagr mutant. During the transposon
mutant screen, phenotypic similarities between transposon insertions in 1984 and agrB
were observed. The similarities between these two mutants included major defects in
bacterial protein secretion and increased IL-1β secretion by macrophages (Figure 3). The
Agr system is a major regulatory system in S. aureus that is involved in surface protein
expression as well as virulence factor production and it contributes to the pathogenesis of
S. aureus during infection. Based upon the influence of the Agr system on pathogenesis
and the similarities between the transposon insertion mutants of 1984 and agrB, I decided
to investigate similarities between in-frame deletion mutants of 1984 and agr, and
compared their protein secretion profiles, virulence factor production, ability to induce
macrophage activation, and pathogenesis in vivo. As a 1984 transposon insertion mutant
displayed similar phenotypes to a transposon insertion mutant in agrB, I hypothesized
that a Δ1984 mutant would display similar phenotypic markers associated with Agr
deficiency such as reduction in secreted proteins, decreased virulence factor expression,
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increased surface protein expression, and altered macrophage activation compared to
wild type S. aureus. Consistent with the findings of the transposon mutants, I found that a
Δ1984 mutant phenocopies a Δagr mutant for defects in protein secretion in both rich and
defined media (Figure 6).

Figure 6. A Δ1984 mutant resembles a Δagr mutant for defects in protein secretion. Exoprotein
profiles from wild type, a Δ1984 mutant, and a Δagr mutant grown in rich (TSB) and defined (RPMI)
medium for eight hours.

To verify results seen during the transposon mutant screen as well as to compare
the roles of 1984 and the Agr system in macrophage activation, I repeated the abovedescribed macrophage cytokine assay with a Δ1984 mutant. If a Δ1984 mutant were
defective in protein secretion similar to a Δagr mutant, then I would expect to see a
similar pro-inflammatory cytokine response when bone marrow derived macrophages are
treated with supernatant from a Δ1984 mutant and a Δagr mutant. I found that
supernatant from a Δ1984 mutant and a Δagr mutant altered macrophage cytokine
secretion in a similar manner. The supernatants of both strains induced significantly
higher levels of IL-1β secretion, but led to decreases in the levels of IL6 and KC
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compared to supernatant from wild type or Δ1984+1984 strains (Figure 7). The
similarities in cytokine secretion profiles after treatment of macrophages with supernatant
derived from Δ1984 and Δagr mutants provided the first evidence that the functions of
1984 and agr might converge, leading to similar in vitro and in vivo phenotypes.
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Figure 7. A Δ1984 mutant phenocopies a Δagr mutant for macrophage immunomodulation. Murine
bone marrow derived macrophages were incubated with cell free supernatant from wild type S. aureus,
Δ1984, Δ1984+1984, Δagr, and Δ1984Δagr for 24 hours. CBA was performed on macrophage
supernatant. Data shown are a representative experiment with triplicate values. A one-way ANOVA was
used to evaluate the significance of the data.

Based on the similarities between exoprotein profiles and macrophage activation
between a Δ1984 and a Δagr mutant, we would expect other well-known regulatory
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patterns associated with Agr deficiency to also be the same. The Agr pathway is involved
in regulating virulence factors such as Protein A and leukotoxins in an opposing manner
such that Protein A expression is decreased and leukotoxin expression is increased upon
induction of the Agr pathway. Therefore, I evaluated Protein A and leukotoxin protein
expression levels in a Δ1984 mutant. Because a Δagr mutant cannot induce production of
RNAIII to elicit its regulatory functions, a Δagr mutant has increased expression of
Protein A, but decreased expression of leukotoxins such as LukAB and LukED. If the
hypothesis that Δ1984 phenocopies Δagr is correct, we would expect a Δ1984 mutant to
also have increased Protein A and decreased LukAB and LukED compared to a wild type
strain. This hypothesis was tested by comparing virulence factor expression by
immunoblots. Protein A levels were increased in both Δ1984 and Δagr compared to the
wild type or the Δ1984 +1984 complement strain. In contrast, the leukotoxin levels were
decreased in a Δ1984 mutant and a Δagr mutant (Figure 8). Another secreted factor
whose expression is positively regulated by the Agr system is the alpha toxin, the primary
red blood cell lysing toxin of S. aureus. Therefore, a Δagr mutant exhibits decreased
hemolytic activity when on a blood agar plate compared to wild type S. aureus (Data not
shown). Similarly, a Δ1984 mutant is ineffective at creating a zone of clearance
compared to wild type or Δ1984+1984 (Figure 9). Together, these data provide clear
evidence that a Δ1984 mutant behaves similarly to a Δagr mutant.
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Figure 8. A Δ1984 mutant phenocopies a Δagr mutant for increases in Protein A expression and
decreases in leukotoxin expression. Immunolots were performed on supernatant samples collected after 8
hours of growth. A rabbit anti-LukA antibody and a rabbit anti-LukE antibody were used for
immunodetection.

Figure 9. A Δ1984 mutant has decreased hemolysis compared to wild type S. aureus. Strains were
struck on a blood agar plate and grown at 37°C overnight.
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Assess whether 1984 is involved in processing AgrD and generating functional AIP.
Introduction. Since a Δ1984 mutant phenocopies a Δagr mutant for exoprotein
profile defects, alterations in virulence factor production, and macrophage activation, we
hypothesized that 1984 may have a functional role in Agr system activation. As
previously described, the Agr quorum-sensing system is comprised of a response
regulator, AgrA, a histidine kinase, AgrC, the AIP peptide precursor, AgrD, and a
transmembrane protein, AgrB (Figure 1A). The current literature indicates that AgrB is
involved in AgrD post-translational processing by cleaving the C-terminal end of the
peptide (48) as well as secreting processed AIP (9)(Figure 1B). In addition, Kavanaugh
et. al. put forward the hypothesis that the Type I Signal Peptidase, SpsB, is responsible
for cleaving the N-terminus of AgrD, however a number of weaknesses in the study
design suggest that SpsB is an unlikely candidate for peptide processing (See Literature
Review) (23). Therefore, the enzyme involved in cleaving the AgrD N-terminus remains
unknown. Given this information along with my preliminary data, I hypothesized that
1984 is the peptidase responsible for cleaving the N-terminal end of AgrD. If this
hypothesis were true, then a Δ1984 mutant would not be expected to produce functional
AIP, thereby rendering the Agr system inactive.
AIP production is compromised in a Δ1984 mutant. My preliminary data show
that a Δ1984 mutant functionally mimics a Δagr mutant, suggesting that 1984 is
important for Agr system activation. To test whether or not 1984 facilitates AIP
processing, I first determined if a Δ1984 mutant is able to produce active AIP, with the
expectation that if 1984 is involved in AgrD peptide processing then a Δ1984 mutant
would either not secrete AIP at all or would release a non-functional processing
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intermediate. The presence or absence of active AIP can be measured by applying filtered
culture supernatants to an AIP-responsive reporter strain. I used a Δ1984 mutant, as well
as a Δagr mutant, that contained a reporter plasmid, pDB59, which contains the P3
promoter from the Agr system controlling gfp transcription. Addition of supernatant that
contains functional AIP will induce the P3 promoter, leading to the production of GFP
that can be measured with a fluorescence plate reader. In contrast, supernatant that lacks
functional AIP, such as supernatant derived from a Δagr mutant, will fail to induce high
levels of GFP. As expected, the control Δagr + pDB59 mutant does not produce GFP
even in the presence of supernatant with fully processed AIP, which is consistent with the
lack of AgrA and AgrC in this mutant (Figure 10). Additionally, supernatants from wild
type S. aureus or Δ1984+1984 both induced GFP production by Δ1984+pDB59, while
supernatant derived from a Δagr mutant failed to induce GFP production. Finally, I asked
if supernatant derived from a Δ1984 mutant can induce P3 promoter activity, and found
that Δ1984 supernatant did not induce GFP production. From these results I can conclude
that a Δ1984 mutant does not produce properly processed AIP and that the Agr pathway
is defective at the level of AIP production since activity can be fully restored by adding
processed AgrD to a Δ1984+pDB59 reporter strain.
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Figure 10. A Δ1984 mutant does not produce functional AIP. A Δ1984 mutant and a Δagr mutant
containing a pDB59 plasmid with the P3 promoter of the Agr system promoting the expression of GFP was
incubated with cell free supernatant from wild type, Δ1984, Δ1984+1984, and Δagr. In the presence of
properly processed AIP, in a genetic background containing AgrA and AgrC, gfp expression is induced.
Statistical analyses were done using two-way ANOVA. **** P<0.0001.

Designing 6x-His-AgrD expression plasmids to evaluate 1984-dependent peptide
processing.
(1) Native promoter expression. My P3-gfp reporter assays demonstrated that a
Δ1984 mutant cannot produce functional AIP as evidenced by a lack of promoter activity
in the presence of conditioned medium derived from a Δ1984 mutant. Furthermore, 1984
has predicted peptidase activity based on bioinformatics analysis. Given this information,
I hypothesized that 1984 is involved in cleaving the N-terminal end of AgrD to generate
functional AIP. To test this hypothesis I sought to visualize AgrD cleavage events by
immunoblot, similar to those used to investigate the involvement of AgrB in C-terminal
AgrD cleavage (11, 12, 58). If 1984 is involved in AgrD cleavage, then I should be able
to visualize alterations in peptide lengths in the presence and absence of 1984 by
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evaluating shifts in the molecular weight of 6x-His-tagged peptide fragments after
immunoblotting with monoclonal anti-6xHis antibody as illustrated in Figure 11.

Figure 11. Expected results of AgrD cleavage. Wild type, a Δ1984 mutant, a Δagr mutant, as well as
Δ1984Δagr double mutant strains containing AgrD with a 6x-His-tag on either the C-terminal end or Nterminal end of the peptide should display varying AgrD processing intermediates.

In order to visualize alterations in peptide lengths in the presence or absence of
1984, I first needed to express 6x-His-tagged AgrD in wild type, Δ1984, Δagr, and
Δ1984Δagr strains. Under normal conditions, the expression of AgrD peptide is driven
by a promoter known as P2. P2 promoter activity is sufficient to generate enough AIP to
activate the Agr system in culture and is presumably detectable by immunoblot.
Therefore, I first generated two native promoter AgrD expression vectors that kept
expression of AgrD under the regulation of its native P2 promoter. These two constructs
encoded AgrB and either a C-terminal 6x-His-tagged AgrD or an N-terminal 6x-Histagged AgrD (Figure 12A). Of note, inherent in use of the native promoter constructs is
agrB, which precludes assessment of peptide cleavage events independent of the AgrB
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protease even in Δagr, and Δ1984Δagr strain backgrounds. After growing strains
containing these 6x-His-AgrD promoter constructs in RPMI medium for 8 hours,
followed by collection of supernatant and whole cell lysates, I determined that I was not
able to detect 6x-His-AgrD or AgrD-6x-His using either of the native promoter
expression strains (data not shown). The lack of detection in this study suggests that the
concentration of AgrD expressed from its native promoter is insufficient to permit
detection of the peptide by immunoblot, therefore alternate expression strategies may be
more adequate and should be tested.

Figure 12. Illustration of 6x-histidine-tagged AgrD constructs. Expression plasmids were generated to
drive AgrD expression under the control of: (A) its native P2 promoter, (B) a hemin inducible promoter
Phrt , (C) constitutive promoters Plgt and PHELP and (D and E) the highly transcribed promoter, PSarA,
containing an optimal ribosomal binding. In order to troubleshoot issues with detection of the N-terminal
6x-histidine-tagged AgrD an S-tag was used as a linker region between the 6x-histidine-tag and AgrD in E.
The yellow box represents the location of the 6x-histidine-tag.
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(2) Hemin-inducible expression. It was clear from native promoter 6x-His-AgrD
expression studies that AgrD was produced in insufficient quantities to permit
visualization of peptide cleavage by immunoblot. Further, the presence of agrB in our
native promoter expression constructs precluded our direct assessment of AgrBindependent cleavage. One method commonly used to enhance expression of target genes
for downstream analysis is to drive expression under an inducible promoter. A number
of S. aureus specific inducible promoters have been used including the hemin-inducible
promoter Phrt. Therefore, I sought to improve detection of 6x-His-AgrD by generating
expression plasmids with either the N-terminal or C-terminal 6x-His-AgrD under the
control of the Phrt promoter (Figure 12B). With this expression vector I expected to
induce a high level of 6x-His-AgrD upon addition of hemin that would be easily detected
by immunoblot. After induction with concentrations of hemin that are not bactericidal
and subsequent immunoblot, I still was unable to detect 6x-His-AgrD. Increased hemin
concentrations that promote gene expression further were compromised by secondary
toxic effects associated with adding excess hemin (data not shown). Together, these
observations indicate that use of hemin-inducible promoter, Phrt, is insufficient to permit
high level expression and immunodetection of AgrD.
(3) Constitutive promoter expression. The hemin-inducible promoter Phrt did
not elicit high enough expression for immunodetection of AgrD without imposing
significant cytotoxic effects. As an alternative approach to using this inducible expression
plasmid, I sought to obtain detectable concentrations of 6x-His-AgrD using constitutive
promoters in a multi-copy plasmid to drive 6x-His-AgrD expression. Two promoters
commonly used in the S. aureus research community for constitutive expression are the
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lipoprotein diacylglycerol transferase (Plgt) promoter and the high expression in Listeria
promoter (PHELP). Therefore, to drive expression of 6x-His-AgrD, I created pOS1
expression plasmids with either Plgt or PHELP promoters driving agrD gene expression
(Figure 12C). I expected these constructs to produce a large enough abundance of 6x-Histagged AgrD to be detected by immunoblot, however none of these constructs led to
detectable 6x-His-AgrD (data not shown). In sum, these studies indicated that, although
6x-His-tagged AgrD expression was under the control of constitutively expressed
promoters, it is not expressed at high enough concentration for immunodetection.
(4) Use of high level overexpression vectors. 6x-His-tagged AgrD is
undetectable by immunoblot even when constitutively expressed from the Plgt or PHELP
promoters. This was surprising, given the routine use of these promoters to express genes
in S. aureus. However, given this finding I needed to devise an alternative method to
express 6x-His-AgrD. An additional highly expressed promoter that is routinely used to
overexpress proteins in S. aureus is PsarA. This particular sarA promoter is one of three
promoters used by S. aureus to control the expression of the Staphylococcal accessory
regulator (SarA). PsarA is highly expressed in S. aureus and does not appear to be under
additional regulatory control. Therefore, to attempt to achieve a detectable amount of 6xHis-tagged AgrD for immunoblot, I generated constructs using a multi-copy plasmid,
pOS1, containing the PsarA promoter and an optimized ribosomal binding site derived
from the superoxide disumutase (sod) gene in S. aureus (Figure 12D). By over expressing
the 6x-His-AgrD constructs I would expect to produce a high enough concentration of
6x-His-tagged AgrD to be detectable by immunoblot. Using this overexpression plasmid,
I was finally able to detect the C-terminal 6x-His-tagged AgrD in whole cell lysates and
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supernatant however I was still unable to detect the N-terminal 6x-His-AgrD (Figure 13).
Together these data indicate that generation of sufficient quantities of ArgD for
immunodetection requires significant overexpression from S. aureus and suggests that Nterminal 6x-His-AgrD may not be stable.

Figure 13. Detection of the C-terminal 6x-histidine-tagged AgrD in whole cell lysates and
supernatant. C-terminal 6x-histidine-tagged AgrD is detectable when expression is driven by the pOS1pSarA- sodRBS over- expression plasmid after 8 hours growth in RPMI .

Improving resolution and reproducibility in detection of 6x-His-AgrD by
immunoblot. Although I was able to detect C-terminal 6x-His-tagged AgrD, my
immunoblot results were not reproducible. I reasoned that the lack of reproducibility
could either be due to degradation of the AgrD peptide product or improper immunoblot
conditions. Therefore, I continued to repeat these experiments, with the aim of optimizing
the resolution of my immunoblots in order to detect possible cleavage events and
improve inter-experiment variability. The two major changes I made were to (i) use
Tricine-SDS-PAGE gels as described by Schägger to enhance resolution of small
peptides less that 10 kDa (59) and (ii) expose my Western blots on film instead of using
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the Protein Simple, which routinely gives irregular signal detection when protein
abundance is low. Upon incorporation of these experimental changes, my results were
much more consistent across experiments. One notable feature of these improved
immunoblots was the detection of AgrD in greater abundance in strains lacking 1984
(Figure 14). However, it was still difficult to draw conclusions about alterations in size
due to presumed gel overloading and resultant poor resolution (Figure 14). Nonetheless,
these data indicated that, in the absence of 1984, AgrD is present in greater abundance
within whole cell lysates and may suggest an important role for 1984 in facilitating
localization of AgrD in the cell.

Figure 14. Differences in AgrD cleavage events may be visible when using Tricine-SDS-PAGE gels
exposed to film. Representative immunoblot after running protein sample from whole cell lysates on a
Tricine-SDS-PAGE gel. Immunoblot exposed to film for 5 minutes.

AgrD processing is altered in Δ1984, Δagr, Δ1984Δagr mutant backgrounds.
Although I was now able to achieve reproducible immunodetection of C-terminal 6x-HisAgrD, and observed an increased abundance of cell associated AgrD in Δ1984 mutant
backgrounds, I still could not draw firm conclusions on size changes because the
immunoblots were overloaded with sample. Based on my results, I hypothesized that my
current method of normalizing samples (optical density) was not suitable for detection of
shifts in peptide length, due to the increased abundance of AgrD in the lysates of all
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strains lacking 1984. To prevent overloading of the strains, I altered my protocol and
began loading gels based on relative abundance of the protein, rather than normalizing to
the amount of bacteria present. To further improve resolution, I began running longer
gels at a higher percentage of acrylamide in the presence of 6 Molar urea. I anticipated
immunoblots conducted with these alterations would improve visualization of shifts in
size that might correlate with AgrD processing. This was indeed the case, as the wild type
and Δ1984+1984 samples ran at a discernibly higher molecular weight then the other
AgrD species derived from Δ1984, Δagr and Δ1984Δagr mutants (Figure 15). Although
the wild type and Δ1984+1984 results where unexpected , I suspect the higher molecular
weight species in the wild type and Δ1984+1984 samples could correspond to full length
unprocessed AgrD with no detectable processing intermediates. Processing and secretion
of AgrD may be happening much faster in these strains and therefore processing
intermediates are either secreted or degraded. An alternate possibility is that the
visualized band is processed AgrD with an inappropriately formed thiolactone ring,
which could potentially affect how the peptide is running through the gel. Nonetheless,
these results indicate that a discernable difference in AgrD migration is observed for WT
and Δ1984+1984, implying 1984 and agrB are both influencing peptide processing to
some degree.
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Figure 15. Visualization of AgrD cleavage events is enhanced after normalizing to protein
abundance. Representative immunoblot after running protein sample from whole cell lysates on a 21%
Tricine-SDS-PAGE gel with 6M urea. Immunoblot exposed to film for 10 minutes.

Improving detection of AgrD processing intermediates. Although I have
detected what appear to be alterations in migration associated with C-terminal 6x-Histagged AgrD derived from different strains, I would have expected to be able to detect
processing intermediates present within a single well based on prior studies in the
literature. There are several possible explanations for the lack of detection of processing
intermediates in my samples. The first possibility is that my sample preparations do not
adequately solubilize all AgrD peptide processing intermediates. To overcome the
possibility of solubility issues I have attempted alternate whole cell lysate preparations.
During these cell lysate preparations I boiled the samples in 6x-SDS buffer before
centrifuging out the glass beads and cell debris. By changing the order 6x-SDS addition
in this way, I anticipated that I would better solubilize more protein including AgrD
intermediates. However, upon generating these preparations, it seems they contained too
much cellular debris causing the samples to run unevenly through the gels making
determination of shifts in size increasingly difficult (results not shown).
Although I was unable to rule out poor solubility as a cause of undetectable
peptide processing intermediates, I hypothesized that the AgrD processing intermediates
might alternatively be at too low a concentration, or might be degraded so rapidly that
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they are not detected by immunoblot. Therefore, I first attempted to increase the amount
of 6x-His-tagged processing intermediates by concentrating my samples using affinity
chromatography with nickel resin. However, this method did not yield reproducible
detection of 6x-His-tagged AgrD or alternate processing events by immunoblot (results
not shown). I then attempted to overcome potential degradative processes by adding
protease inhibitor to my lysate preparations. However, the protease inhibitor treatment
did not allow for detection of any additional bands by immunoblot (results not shown).
Together these data have not been able to conclusively determine the reason for my
inability to detect AgrD peptide processing intermediates. While not yet able to draw firm
conclusions about peptide processing from these studies, I have set the groundwork for
how this experiment will need to be done to yield positive results in the future.
Attempt to detect N-terminal 6x-His-tagged AgrD by immunoblot. Although I
was able to successfully detect C-terminal 6x-His-tagged AgrD and potentially ascertain
some role for 1984 and AgrB in peptide processing, I have not yet been able to detect Nterminal 6x-His-tagged AgrD under any of the previously described conditions. Nterminal 6x-His-AgrD has been used for immunodetection studies in the literature and
was found to be superior to C-terminal 6x-His-tagged AgrD whose processing
byproducts are often rapidly degraded. Because N-terminal 6x-His-tagged AgrD was
used routinely in studies exploring the AgrB-dependent peptide processing, I returned to
the literature to try to understand why I was unable to detect the N-terminal 6x-Histagged AgrD constructs that I originally generated. Several papers have successfully
tagged the N-terminus of AgrD in order to detect peptide processing, but I found that they
often required a “linker” between the 6x-His-tag and the N-terminal end of AgrD (11, 12,
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58). Based upon this observation, I generated new expression plasmids, still using pOS1PsarA- sodRBS, but now with a linker region between the 6x-His-tag and AgrD (Figure
12E). I chose to include a 45 nucleotide “S-tag” linker between the 6x-His and AgrD, as
this construct had been previously used by Alex Argianas to successfully purify AgrD. I
expected that the addition of the linker region would allow for detection of N-terminal
6x-His tagged AgrD by immunoblot. Although incomplete, these results were promising
as I was able to detect N-terminal 6x-His-tagged AgrD in a few of the strains tested
(Figure 16). Detection of the N-terminal 6x-His-tagged AgrD will need to be further
optimized in order to be able to make any conclusions on peptide processing by
immunoblot.

Figure 16. N-terminal 6x-histidine-tag is detectable when there is a linker. Immunoblot
after running protein sample from whole cell lysates on a 21% Tricine-SDS-PAGE gel with 6M urea.
Immunoblot exposed to film for 5 minutes.

Use of purified AgrD to evaluate 1984-dependent peptide processing. The
immunoblots generated using 6x-His-tagged AgrD peptide expression strains do not
currently provide sufficient evidence for the involvement of 1984 in AgrD peptide
processing. Because we have had difficulties generating sufficient peptide concentration
for reliable immunodetection, I decided to attempt an alternate method to determine the
involvement of 1984 in AgrD peptide processing. I initiated experiments using membrane
fractions from wild type, Δ1984, Δ1984+1984, Δagr, or Δ1984Δagr strains along with
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purified AgrD to evaluate cleavage events of the purified peptide. Alex Argianas has
been working on purifying AgrD, 1984, and AgrB for use in biochemical studies. I was
able to attempt an experiment where I applied partially purified AgrD to membrane
fractions in an in vitro cleavage assay. From this assay, I would expect to be able to
visualize alterations in AgrD peptide cleavage in a similar manner as the immunoblots
described above (see figure 11). Unfortunately, purified AgrD levels were too low in this
initial purified preparation to visualize peptide processing by immunoblot (Data not
shown). Once we have more concentrated preparations of AgrD to work with these
studies can be further optimized.
Assess the role of 1984 in altering immune function during S. aureus infection.
Introduction. I have shown increased macrophage secretion of IL-1β in vitro
after treatment with supernatant derived from a 1984 mutant (Figure 7) and that 1984 is
likely involved in AgrD peptide processing (Figure 10). If these phenotypes are
recapitulated in vivo they could have significant effects on immune cell recruitment and,
in turn, bacterial virulence characteristics. For example, IL-1β is a cytokine produced by
activated macrophages and is involved in neutrophil recruitment as well as promoting a
proinflammatory immune response. Thus, dramatic shifts in IL-1β expression during
infection would be expected to dramatically alter the cellular immune environment.
Furthermore, if the Agr system is not functioning appropriately, the regulation of
virulence factors will no longer maintain optimal expression kinetics. Without this
regulation, S. aureus can lose its ability to evade immune surveillance mechanisms,
thereby compromising its survival in vivo. For these reasons, I hypothesize that the
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Δ1984 mutant will be attenuated in multiple in vivo infection models similar to a Δagr
mutant.
1984 and the Agr system are critical during skin and soft tissue infections. S.
aureus frequently causes localized disease in the skin and Agr activity is known to be
critical for S. aureus virulence in the skin of mice (28). Therefore, I used a murine skin
and soft tissue infection model to study the involvement of 1984 during in vivo infection.
This mouse model measures localized infection events that do not easily disseminate.
Female ND4 Swiss Webster mice were infected with WT, Δ1984, Δ1984+1984, and
Δagr in the right and left flank, followed by monitoring disease at 72 and 120 hours postinfection. At 72 hours post infection (Figure 17A and C), there was not a significant
difference in bacterial CFU recovered from abscess sites between any of the strains tested
indicating that Agr and 1984 are likely not involved early in S. aureus infection of the
skin. Additionally, many of the abscesses at this time point were similar regardless of
bacterial strain, although Δ1984 and Δagr showed a trend toward reduced abscess size
(Figure 17C). At 72 hours a larger number of wild type and Δ1984+1984 infected
abscesses were starting to rupture compared to those infected with a Δ1984 or Δagr
mutant. When we carried the infection out to 120 hours (Figure 17B, D), we saw that a
Δagr mutant was significantly attenuated (Figure 17B). Similarly, we saw that a Δ1984
mutant had significantly decreased CFU in the skin abscesses compared to wild type
infected abscesses (Figure 17B). These differences in CFU are clearly reflected by the
gross pathology differences observed in the abscesses (Figure 17D). At 120 hours post
infection, wild type and Δ1984+1984-infected animals had inflamed, dermonecrotic
abscesses that had ruptured. In contrast, mice infected with either a Δ1984 or a Δagr

62

mutant had very little apparent inflammation in what seem to be resolving abscesses.
Serum and skin samples were collected at each time point to analyze cytokine levels by
CBA. At 72 hours post infection in the skin, IL-1β levels were higher during infection
with a Δ1984 mutant compared to the others, similar to what we had shown in vitro
(Figure 18). Although, these results were not statistically significant this trend toward
increased IL-1β closely resembles the macrophage cytokine secretion levels seen in vitro
upon treatment with Δ1984 supernatant, and may provide some insight into the
alterations in immune responses that influence infection kinetics of Δ1984 infected
animals, such as clearance of the bacteria and decreased tissue damage. By 120 hours
post-infection both a Δ1984 and a Δagr mutant had much less IL-1β in their abscesses
than wild type and Δ1984+1984. Perhaps this modulation of IL-1β secretion early in
infection provides evidence for why a Δ1984 mutant is so readily cleared at 120 hours, as
early transient high levels of IL-1β would increase the immune cell recruitment to
promote restriction of bacterial infection. At 72 hours, Δagr infected mice did not exhibit
increased IL1-β levels, suggesting these two mutants may exhibit differing mechanisms
of cytokine induction. On a whole, these data indicate 1984 and Agr are crucial to
pathogenesis in a skin and soft tissue infection model. Furthermore, although preliminary,
the data are suggestive of a role for IL-1β in the early immune recognition and clearance
of 1984 mutant. Additional studies are needed to lend credence to this notion.
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Figure 17. 1984 and the Agr system are critical during skin and soft tissue infections. A skin and soft
tissue infection model was used in which mice were infected intradermally with 1x10 7 CFU of bacteria in
the presence of Cytodex beads in both the right and left flank. 72 hours (A) or 120 hours (B) post-infection
mice were sacrificed and skin abscesses were collected to enumerate CFU. Representative abscesses (C)
and (D) 120 hours post infection. Each experiment contained cohorts of 4 mice and was performed twice.
Statistical analysis was a Kruskal-wallis test. ** P= 0.0052 and **** P<0.0001.
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Figure 18. A Δ1984 mutant leads to a heightened amount of IL-1β in skin abscesses early in infection.
Abscess homogenates were collected and CBA was performed. One representative experiment is shown.
Each experiment contained cohorts of 4 mice with two abscesses per mouse and was performed twice. A
one-way Anova was used to test for significance of the data.

A Δ1984 mutant does not behave like a Δagr mutant during a peritonitis
model of infection. Using a skin and soft tissue model of infection allowed us to
determine that a Δ1984 mutant as well as a a Δagr mutant are significantly attenuated in a
localized infection model. However this model does not sufficiently test the effects these
mutations have on dissemination. S. aureus-induced peritonitis is an alternative infection
model that can measure infection kinetics as well as dissemination to distal target organs
and immune cell recruitment in a way the skin and soft tissue infection models cannot.
Therefore, use of this model in my studies should provide additional information on the
role of 1984 during more complex infectious scenarios where dissemination is important
to pathobiology. A Δagr mutant is significantly attenuated in the mouse peritonitis
model, therefore if a Δ1984 mutant were attenuated in vivo due to its deleterious effects
on Agr signaling, I would expect a Δ1984 mutant to be attenuated to a similar degree. To
my surprise, a Δ1984 mutant did not phenocopy a Δagr mutant. Although a Δ1984
mutant is slightly attenuated in the peritoneal cavity, it is not attenuated to the same

65

degree as Δagr mutant (Figure 19). Furthermore, a Δ1984 mutant shows signs of
hypervirulence in the kidneys as evidenced by a modest, but not statistically significant,
increase in CFU compared to the wild type strain (Figure 19). Serum and peritoneal
lavage fluid were collected to measure cytokine levels and immune cells were isolated
from lavage fluid and lymph nodes for flow cytometry analysis of immune cell
recruitment to each site. The results from cytokine measurements and immune cell
recruitment were inconclusive as these experiments produced a wide variability in results
(data not shown). Together, these results demonstrated that, in the absence of 1984, S.
aureus is not markedly attenuated during peritonitis. In contrast, a agr mutant is
significantly attenuated. This discrepancy in pathogenic outcomes between a Δ1984 and
Δagr mutant may be indicative of roles for 1984 in vivo that extend beyond its
contribution to Agr system activation.
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Figure 19. A Δ1984 mutant does not behave like a Δagr mutant during a peritonitis model of
infection. Mice were infected IP with 1x108 CFU of bacteria and euthanized 72 hours post infection. Each
experiment contained cohorts of at least 4 mice and was repeated at least 3 times. A kruxkal-Wallis test was
perfomed to determine significance of the data.
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A Δ1984 mutant does not behave like a Δagr mutant during a systemic model
of infection. Since we have extensively evaluated the contribution of 1984 activity in
localized infection models, it was important to also examine the effect a Δ1984 mutant
during systemic infection (sepsis). A systemic infection model is clinically relevant as it
mimics the direct seeding of the bloodstream that can happen after invasive surgery or
during intravenous drug use. Using this model, we can evaluate tissue seeding and
replication without the bottleneck to dissemination that occurs during localized infection
of the skin and peritonitis. In this model, a Δagr mutant typically exhibits modest
attenuation in the kidney. My data recapitulate these results, as a Δagr mutant exhibited
approximately 0.5 log reduction in CFU in the kidney compared to wild type S. aureus
(Figure 20) 96 hours post-infection. In contrast, a Δ1984 mutant was not attenuated in the
kidney (Figure 20). In fact, the Δ1984 mutant had a marked, but not statistically
significant, increase in CFU in the heart compared to wild type S. aureus. These results
indicate that some characteristics of a Δ1984 mutant in vivo are clearly distinct from that
of a Δagr mutant.
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Figure 20. A Δ1984 mutant does not behave like a Δagr mutant during a systemic model of infection.
A systemic model of infection was used in which mice were infected with 1x107 CFU of bacteria by retroorbital injection and 96 hours post-infection mice were sacrificed and organs were collected. Each
experiment contained cohorts of at least 4 mice and was repeated 3 times. A Kruskal-Wallis test was
performed to determine significance. Heart and Liver comparisons were not significant.

Δ1984 derived supernatants contain a unique protein compared to a Δagr
mutant. Taken together, the different virulence phenotypes I witnessed between a Δ1984
mutant and a Δagr mutant during systemic infection and peritonitis were surprising since,
in all other conditions, a Δ1984 mutant closely resembled a Δagr mutant. My results
suggest two possible hypotheses. First, in a Δ1984 mutant there may exist AgrDindependent activation mechanisms in vivo that lead to the production of the virulence
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factors typically under Agr control. Such an outcome would explain the lack of virulence
defect during peritonitis and systemic infection. A second hypothesis is that there is an
additional function associated with 1984 that is not related to Agr, which prevents
attenuation in vivo when 1984 is absent. One piece of evidence in support of this second
hypothesis comes from the exoprotein profiles of a Δ1984 mutant compared to that of a
Δagr mutant (Figure 6) grown in defined medium (RPMI). There is one protein band
present in a Δ1984 mutant that is not present in a Δagr mutant that runs at around 27 kDa
in an SDS-PAGE gel. To begin to understand this difference between a Δ1984 mutant
and a Δagr mutant I first completed an eight hour growth curve in which I collected
samples every two hours in order to look at the exoprotein profiles of wild type, Δ1984,
Δ1984+1984, and Δagr strains. The presumptive band is apparent in the first four hours
of growth of all strains. However, by hour 6 the band was no longer present in the
exoprotein profile of any strain except for the samples from a Δ1984 mutant (Figure 21).
Therefore, I identified this protein by mass spectrometry and the results came back with
one statistically significant match, the immunodominant Staphylococcus antigen A or
IsaA (60, 61). IsaA was only present in the supernatant of a Δ1984 mutant and was not
identified in the wild type sample. IsaA is a soluble lytic transglycosylase that was first
discovered as an antigen that leads to the production of an immense amount of antibody
in infected patients (60). A hyperinflammatory immune response is triggered by the
recognition of peptidoglycan released by IsaA during cell division (62). It is also worth
noting that IsaA is not regulated by the Agr system (62). A Δ1984 mutant mimics the
deficiencies we see in secretion caused by a Δagr mutant except for IsaA production.
Thus, it does not seem IsaA upregulation is related to the roles of 1984 in Agr system
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activation. These data provide insights into unique alterations in secreted proteins of a
Δ1984 mutant that have direct links to virulence and that are not seen for a Δagr mutant.

Figure 21. Identification of protein present in supernatant of a Δ1984 mutant and not in a Δagr
mutant. Samples were grown in RPMI, at 37°C with shaking at 200 rpm. Suppernatants were collected
every 2 hours for 8 hours. The red box highlights the area of the protein of interest.

Conclusions
I have shown that a Δ1984 mutant displays phenotypes similar to a Δagr mutant
including defects in protein secretion, reduction of virulence factor expression, and
altered macrophage activation. On a whole I submit that my findings help support the
hypothesis that 1984 is involved in cleaving the N-terminal end of the AgrD peptide in
order for S. aureus to produce functional AIP. Additionally, The virulence characteristics
I have observed for a Δ1984 mutant in multiple in vivo studies have provided a unique
perspective into our understanding of the complex functions of 1984 during infection as
well as provide future avenues for the lab to explore.
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CHAPTER FOUR
DISCUSSION
1984 is a putative peptidase involved in the processing of key signaling peptides.
The goal of this thesis was to investigate the role of 1984 in S. aureus quorum
sensing and pathogenesis. My studies have revealed that 1984 plays a major role in
facilitating quorum sensing, potentially peptide processing, and modulation of the
immune response. Using an in-frame deletion mutant of 1984, I have demonstrated
phenotypic similarities to a mutant in a major quorum sensing system in S. aureus
involved in regulation of surface proteins and secreted virulence factor gene expression.
A Δ1984 mutant phenocopies a Δagr mutant for defects in protein secretion, virulence
factor production, and modulation of macrophage cytokine secretion. At this point the
assessment of these phenotypic similarities are purely qualitative, therefore quantification
by measuring relative virulence factor abundance in western blots as well as
quantification of hemolytic activity using numerical methods is warranted. Additionally,
1984 is predicted to have peptidase function. Based on this information, I hypothesized
that 1984 is involved in processing AgrD by cleaving the N-terminal end of the peptide.
Although I have not obtained direct evidence that 1984 is involved in cleaving the Nterminus of AgrD during AIP processing, I have shown that a Δ1984 mutant is unable to
produce functional AIP.
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Visualizing AgrD cleavage by immunoblot.
Over the course of this study, I attempted to visualize AgrD cleavage events using
strains containing 6x-histidine-tagged AgrD expression plasmids (Figure 11).
Unfortunately, this proved to be more difficult and complex than anticipated. First, I had
trouble detecting the 6x-histidine-tagged AgrD until I used a multi-copy plasmid
containing a highly expressed promoter and an optimized ribosomal binding site. Using
this C-terminal 6x-histidine-tagged AgrD overexpression plasmid, I was able to
reproducibly detect AgrD-6x-His by immunoblot. However, peptide cleavage activity
was difficult to interpret. Rather than detecting the smallest peptide in the wild type and
Δ1984+1984 samples, which would correspond to C-terminal/fully processed peptide, we
detected a band running at a higher molecular weight compared to Δ1984, Δagr, or
Δ1984Δagr. We hypothesize this band corresponds to either full length unprocessed
AgrD with no detectable processing intermediates, or processed AIP containing
inappropriately formed thiolactone ring (Figure 14). Upon further examination of the
literature, the lack of a small molecular weight C-terminal peptide fragment may fit with
the necessity for rapid degradation of the C-terminal cleavage product before additional
AIP can be produced (18). Additionally, I have attempted to process my samples in the
presence of a protease inhibitor. However, this did not allow for detection of additional
cleavage products. I hypothesize that this method was ineffective as the degradation
could have already occurred during the eight hours of growth, leaving too low a
concentration of processing intermediates to be detected by immunoblot. An alternative
approach would be to add protease inhibitor during the eight hour incubation. However,
this may lead to inhibition of AgrD processing or even inhibit growth. Therefore, this
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approach may not be feasible. However, it is also possible that inappropriate thiolactone
ring formation could cause the peptide to aberrantly run in the gel, as this modification
may not be denatured under the current conditions.
I have found that a linker region between the 6x-histidine-tag and the N-terminal
end of AgrD is needed in order to detect the N-terminal tagged AgrD. I predict an Nterminally tagged AgrD may bypass the issues with visualizing C-terminally tagged
AgrD and should provide us with direct evidence as to whether or not 1984 is involved in
cleaving the N-terminal end of AgrD. N-terminal 6x-histidine-tagged AgrD has been
used frequently in similar experiments and the literature suggests the N-terminal end of
AgrD does not seem to degrade as quickly compared to the C-terminus (22).
Additionally, Alex Argianas has been working on purifying AgrD, 1984, and
AgrB for use in biochemical studies that would also provide evidence for the function of
1984 during AgrD processing. Although it remains to be determined, my recently
optimized immunoblot techniques for visualizing 6x-histidine-tagged AgrD; the
construction of a potentially detectable N-terminally tagged AgrD peptide; as well as the
work being done by Alex Argianas will allow us to directly ascertain whether or not 1984
acts to process the N-terminal portion of the AgrD peptide to produce functional AIP.
1984 homologs exist in other Agr-containing bacteria.
As Agr systems are used by many different bacterial species, I wanted to
investigate if 1984 homologs existed in these species. I searched NCBI for homologs to
1984 at the amino acid level in other bacterial species that also have Agr systems and
found that other pathogenic and non-pathogenic species also contain 1984 homologs.
Additional Staphylococcal species that contain highly similar 1984 homologs include
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Staphylococcus haemolyticus (90%), Staphylococcus epidermidis (65%), and
Staphylococcus saprophyticus (51%) (Table3). Other pathogenic bacterial species that
contain Agr systems also have 1984 homologs, such as Listeria monocytogenes (37%),
Enterococus faecalis (54%), Clostridium perfringens (39%), and Bacillus cereus (35%).
Additionally, non-pathogenic Agr-containing species such as Listeria innocua (43%),
Bacillus halodurans (36%), Lactobacillus plantarum (36%), and Clostridium beijerinckii
(30%) also seem to have homologs for 1984. Although the Agr system in S. aureus has
been well studied, the potential involvement of 1984 as a conserved peptidase that
contributes to the activity of other Agr systems in other bacteria that are less well
characterized is an intriguing possibility (63). It would be interesting and important to
identify whether or not these homologs behave like 1984 and if they are involved in
AgrD processing in these other species.
Bacteria

Percent Identity

Staphylococcus haemolyticus

90%

Staphylococcus epidermidis

65%

Staphylococcus saprophyticus

51%

Listeria monocytogenes

37%

Enterococus faecalis

54%

Clostridium perfringens

39%

Bacillus cereas

35%

Listeria innocus

43%

Bacillus halodurans

36%

Lactobacillus plantarum

36%

Clostridium beijerinckii

30%

Table 3. 1984 homologs in other bacterial species.
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A Δ1984 mutant is attenuated during a skin and soft tissue model of infection.
Early during skin and soft tissue infection there is an increase in IL-1β in
abscesses infected with a Δ1984 mutant compared to wild type S. aureus. The increase in
this pro-inflammatory cytokine could lead to enhanced immune cell recruitment,
including neutrophils and other innate cells. With the increase in professional phagocytes
more Δ1984 would be phagocytosed, and without the production of virulence factors
regulated by the Agr system this mutant would not be able to escape the phagosome or
lyse the cells (41, 42). Therefore I suspect the kinetics of IL-1β release in relation to
bacterial clearance from an abscess may be a clear indicator of the mechanism by which a
Δ1984 mutant is attenuated in vivo. However, this requires further exploration. I
envision a deeper investigation and quantification of immune cell recruitment and
inflammation over a time course using histopathology and immunohistochemistry would
help us to better explore the immune activation elicited by a Δ1984 mutant. By looking
over a wider time course, with more time points than the two assessed during this study
we may be able to provide insights into the reasons for such a dramatic attenuation of a
Δ1984 mutant and a Δagr mutant during skin and soft tissue infection as well as gain
insight into the different infection kinetics of these two mutants.
A Δ1984 mutant is not attenuated in other infection models.
Despite the similarities we have shown between a Δ1984 mutant and a Δagr
mutant for defects in protein secretion and virulence factor regulation in vitro, I have
shown that a Δ1984 mutant is not attenuated like a Δagr mutant during systemic infection
and peritonitis. This may indicate that 1984 would not be a good drug target for these
infectious scenarios as a Δ1984 mutant is actually hyper-virulent in certain sites during
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peritonitis and systemic infection. Furthermore, these results suggest two possible
hypotheses; (i) in a Δ1984 mutant there may be an AgrD-independent activation
mechanism in vivo that leads to the production of the virulence factors typically under
Agr control and (ii) there is an additional function associated with 1984 that is not related
to Agr system activity. Although I haven’t ruled out the first possibility, I do have
evidence to support the second hypothesis. When examining the secreted protein profiles
from wild type, Δ1984, and Δagr, I identified an additional protein band present in
supernatant from a Δ1984 mutant and not in the supernatant from a Δagr mutant. This
protein has been tentatively identified as the Immunodominant Staphylococcus antigen A,
IsaA (60, 61). IsaA is a soluble lytic transglycosylase involved in cell division.
Furthermore, IsaA is believed to trigger a hyperinflammatory response because during
cell division IsaA is predicted to release peptidocglycan, which can be recognized by the
components of the immune system. My data suggest that IsaA is down regulated in wild
type S. aureus within 6 hours of growth but is highly expressed in a Δ1984 mutant
(Figure 21). Additionally, IsaA expression is not under Agr control but is positively
regulated by SarA and YycFG, which are two additional regulators in S. aureus (62).
IsaA regulation is complex, but it does not seem that IsaA up regulation in a Δ1984
mutant is related to the role of 1984 in Agr system activation as we do not see an
upregulation of IsaA in a Δagr mutant and isaA is not known to be regulated by Agr.
Although preliminary, the identification of significant amounts of IsaA in Δ1984
supernatant may allude to a role for this product in the altered infection kinetics we have
seen for a Δ1984 mutant during peritonitis and systemic models of infection. To confirm
that the band is IsaA I would want to make a clean mutation in a Δ1984 mutant
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background. I could then coomassie stain the exoprotein profile. If the band is IsaA, then
the band would be no longer be present in a Δ1984ΔIsaA mutant. To test the role of IsaA
during infection with a Δ1984 mutant, I would make a Δ1984ΔisaA double mutant and
repeat the systemic and peritonitis infection models. If the upregulation of IsaA is
responsible for the difference in virulence we see between a Δ1984 mutant and a Δagr
mutant during peritoneal and systemic infection models, then I would expect this
additional mutation would restore a Δ1984 mutant to similar levels of attenuation as a
Δagr mutant in these infection models. The interactions between 1984 and IsaA provide
another unique and interesting relationship to examine in future work.
Clinical therapeutic implication of quorum quenching therapies to treat S. aureus.
Increased incidence of antibiotic resistance among infectious isolates of S. aureus
has necessitated discussion of new drug targets and new therapies. A Δagr mutant is
significantly attenuated during skin and soft tissue as well as peritonitis models of
infection. This would suggest that targeting the Agr quorum sensing system may be an
effective drug target. However, the hyper-virulence of a Δ1984 mutant in peritonitis and
systemic infection models suggests 1984, and perhaps Agr, would not be an optimal drug
target for treatment of invasive disease. Nevertheless, quorum quenching therapeutics
that target Agr have been pursued by a number of research laboratories. The use of
quorum quenching therapeutics relies on three key criteria. The first is that the quorum
sensing system is actively used during infection for virulence (64). Based on the data
presented here, it seems the Agr system is critically involved in pathogenesis during
certain infectious conditions, but not others. Thus, the Agr system partially meets this
criterion. The second assumption is that the quorum sensing system is not essential for
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bacterial growth; therefore there will be less selective pressure for the bacteria to develop
resistance against the therapy (7, 64). A Δagr deletion mutant does not have any growth
defects, therefore the Agr system meets this criterion as well. The final assumption is that
the therapy would be species specific to reduce the off-target effects associated with
antibiotics (64). For example, currently, antibiotic treatment can have serious effects on
microbiota homeostasis. The Agr system is remarkably specific and AgrD peptides often
act only on certain subsets of S. aureus strains. Therefore, the AgrD system fulfills this
final criterion as well.
Given that the Agr system fulfills all primary criteria needed to support the design
of quorum quenching inhibitors it is not surprising that a significant body of research
exists toward achieving this goal. One proposed method of Agr system targeting is
sequestration of the signal peptide, AIP, using antibodies (64). An issue with this method
is that the antibodies used are often highly specific for one Agr group, therefore it would
not be effective against all S. aureus strains. This caveat aside, co-administration studies
with bacteria and AIP-specific antibody does prevent lesion formation in a murine
subcutaneous infection model (65). Additionally, passive immunization with AIP
antibodies limits pathogenicity during lethal challenge (65). Another approach to quorum
quenching is to target the functionality of the system. One chemical inhibitor, savirin,
binds to AgrA, preventing its function (66). In experimental studies savirin treatment did
not provoke a stress response by the bacteria and therefore is not believed to constitute a
significant selective pressure for S. aureus to develop resistance. Nonetheless, an
effective therapeutic derived from savirin has not been realized. Other researchers have
attempted to use proteases as quorum quenching treatments, but proteases tend to have
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broad specificity making enzymatic degradation of peptides a non-ideal treatment option,
as there may be off-target effects (64). Yet another possible quorum quenching therapy
for the Agr system may lie in the fact that there are four Agr groups with specific
sequences and specificity (15, 16). These variants can interfere with and inhibit the
function of other Agr groups. It is predicted that the different variants may isolate
bacterial populations through niche competition (7). Thus peptide analogues of these Agr
groups could be used as a quorum quenching therapy. For example, it has been shown
that synthetic AIP-II reduces abscess formation when coadministered with an infecting
group I S. aureus isolate (19). The downside to AIP group-specific inhibition is that these
treatments are only efficacious against specific strain subsets that harbor the opposing
AIP.
A broad treatment that could act against all Agr groups would be a more favorable
mechanism of quorum quenching over that of group specific inhibition. For example,
Lyon et al. created trAIP-II derived from group II AIP lacking the exocyclic tail (67).
They were able to show that this molecule is able to inhibit all four Agr groups. Although
this potential therapeutic seems promising, it is important to note that Agr defective S.
aureus are detected in colonizing isolates, as well as isolates associated with infection
persistence and bacteremia. These findings indicate that naturally occurring Agr mutants
with infectious potential do still occur in the human host potentially hampering the
therapeutic potential of quorum quenching inhibitors (7). Based on information in the
literature, the Agr system is required during acute infection, but during chronic infection
there is selection for agr mutants because these variants have increased biofilm
formation, antibiotic resistance, and long-term persistence capabilities (7). This suggests
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that the use of the Agr system as a treatment target may only be effective during certain
infectious scenarios (acute disease) or certain infectious sites (skin abscess formation).
Conclusions.
Although this work has not fully defined the roles of 1984 during S. aureus
pathogenesis or gene regulation, we have begun to elucidate its complex functions and
interactions with major quorum sensing circuitry. This work has provided the lab with
techniques that will allow further study of the involvement of 1984 in promoting optimal
Agr system activity. Furthermore, I have provided the lab future avenues to explore in
order to expand on our understanding of the complex functions 1984 may play during
infection.
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